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Abstract: As a key hub of malignant properties, the cancer microenvironment plays a crucial role
intimately connected to tumor properties. Accumulating evidence supports that the lysophospholipid
sphingosine-1-phosphate acts as a key signal in the cancer extracellular milieu. In this review,
we have a particular focus on glioblastoma, representative of a highly aggressive and deleterious
neoplasm in humans. First, we highlight recent advances and emerging concepts for how tumor cells
and different recruited normal cells contribute to the sphingosine-1-phosphate enrichment in the
cancer microenvironment. Then, we describe and discuss how sphingosine-1-phosphate signaling
contributes to favor cancer hallmarks including enhancement of proliferation, stemness, invasion,
death resistance, angiogenesis, immune evasion and, possibly, aberrant metabolism. We also discuss
the potential of how sphingosine-1-phosphate control mechanisms are coordinated across distinct
cancer microenvironments. Further progress in understanding the role of S1P signaling in cancer will
depend crucially on increasing knowledge of its participation in the tumor microenvironment.
Keywords: sphingosine-1-phosphate; cancer; tumor microenvironment; glioblastoma; lysophospholipids;
cancer hallmarks
1. Introduction
Sphingosine-1-phosphate (S1P) represents the simplest natural phosphosphingolipid, and consists
of a single long-chain sphingoid base linked to a phosphate group. Despite its relative simplicity,
and role as intermediate metabolite in the catabolism of complex sphingolipids, S1P exhibits an
extraordinary array of cell functional properties strictly related to cancer. Indeed, S1P is an important
signaling molecule, able to stimulate proliferation, motility, migration, and survival of many cell types,
both normal and malignant [1]. The multiplicity of S1P roles are mainly exerted through its unique
inside-out signaling, via a family of five S1P-specific G protein-coupled receptors (named S1P1–S1P5) [2],
differentially expressed in different cell types. In addition, S1P can also act as an intracellular signal,
targeting different cellular proteins, and regulating histone acetylation and transcription [1,3,4].
Aberrant S1P metabolism, receptor expression, and signaling emerged as relevant contributors
to initiation, progression, and malignant properties of different tumors [5–8], and, among them,
glioblastoma (GBM) [9–11], one of the most aggressive neoplasms in humans.
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After introducing the key features of S1P signaling and of GBM, we here review our current
understanding of how different tumor and normal cells in cancer niches contribute to alterations of S1P
homeostasis and signaling, and impact cancer hallmarks, progression and properties. We here focus on
the emerging fields relevant to GBM as representative of highly malignant and dreaded form of cancer.
2. S1P Metabolism and Export
S1P homeostasis is tightly regulated by the balance between its synthesis and degradation in a
metabolic process orchestrated by several metabolic enzymes [1,12]. The biosynthetic precursor for the
synthesis of S1P is sphingosine, derived from the hydrolysis of ceramide during the degradation of
sphingomyelin and glycosphingolipids [13]. S1P is then formed through the transfer of the γ-phosphate
from adenosine triphosphate (ATP) to sphingosine, catalyzed by two isoenzymes of sphingosine kinase
(SphK), namely SphK1 and SphK2. Both SphKs are subject to complex temporal and spatial regulation
by multiple mechanisms, including transcriptional, translational, and post-translational ones, as well
as subcellular and extracellular localization (see [14–16] for recent reviews).
Each SphK isozyme has variant isoforms differing only at the N-terminus [14]. Despite the
fact that SphKs catalyze the formation of S1P, their product may have not only overlapping but
also divergent functions within the cell, with these differences dictated also by their differential
subcellular localization [17–20]. SphK1 is mainly cytoplasmic, whereas SphK2 localizes to several cell
compartments depending on the cell type [21]. In response to different stimuli, both isoenzymes can
acutely associate with different cell membranes, such as plasma membrane, mitochondrial-associated
membranes, endosomal vesicles and phagosomes [22]. Moreover, although most S1P is synthesized
intracellularly, its production may partially occur extracellularly through SphKs secreted by some cell
types. Extracellular export of SphK1 was reported in vascular endothelial and HEK293 cells [23,24],
and pre-apoptotic cells extracellularly release a SphK2 fragment which is enzymatically active [25].
Recently, considerable attention has been given to the role of SphKs in cancer, and of SphK1
in particular. In multiple types of cancers, elevated expression of SphK1 occurs, and the following
production of S1P promotes cell survival, growth, and invasiveness [7,14,26]. In addition, a role for
SphK2 in cancer emerged from studies demonstrating that high expression of SphK2 in human cancers
is linked to poor patient prognosis [27].
S1P catabolism involves two major, alternative reactions. One is the irreversible cleavage of
S1P to form hexadecenal and ethanolamine phosphate. This degradation reaction represents the last
step in sphingolipid catabolism, catalyzed by S1P lyase, an enzyme located in the membrane of the
endoplasmic reticulum (ER), with the catalytic domain facing the cytosol [28]. Alternatively, S1P can
be dephosphorylated back to sphingosine, through either two specific, ER-localized S1P phosphatases
(SPP1 and SPP2), or by three broad-specificity, plasma-membrane-located lipid phosphate phosphatases
(LPP1-3) [29,30].
It was more than 20 years ago that intracellular S1P metabolism, including its rapid enzymatic
interconversion to and from ceramide, gave rise to the sphingolipid rheostat model, whereby the balance
between S1P (pro-proliferative, pro-survival) and ceramide (anti-proliferative, pro-differentiating,
pro-apoptotic) exerts a crucial influence over normal and cancer cell fate [31,32]. This model has
been substantiated in many reports on cancer investigations, and, along with time and the increased
knowledge on the complexity of S1P signaling, it has been recently updated with the inclusion of the
“inside-out” signaling by the S1P/S1P receptor (S1P1-5) axis [20]. Indeed, crucial in S1P function is its
extracellular export, which occurs from different but not all cell types after intracellular generation.
The cellular efflux of S1P into the extracellular environment can be mediated by several transport
proteins, such as different members of the ATP-binding cassette transporters (ABCTs), Spinster 2
(Spns2) [33–35], as well as the major facilitator superfamily domain-containing 2b (Mfsd2b), recently
identified in red blood cells [36]. Due to the efficient export by red blood cells and endothelial cells (ECs),
relatively high concentrations of S1P compared with solid tissues are present in plasma [37], creating a
gradient of high S1P levels in blood vs. tissues, functionally important for S1P biological properties.
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3. Glioblastoma
Glioblastoma (GBM) is the most common type of malignant primary brain tumor in adults
typically presenting as primary GBM [38]. This cancer represents a unique clinical challenge as it
has strong resistance to traditional therapies, it can spread aggressively to other areas of the brain,
and it may occur in susceptible areas where treatments easily cause damage to adjacent healthy
tissue. In addition, the tumor itself is characterized by heterogeneous areas of necrotizing tissue and
peritumoral oedema, and are often asymptomatic until reaching a large size [39]. The deleterious
malignancy of GBM is exemplified by the median survival of its patients, which is only about three
months without prompt treatment [40]. Current GBM therapies include surgery, radiation therapy,
and chemotherapy. However, even with these therapies, the average survival of GBM patients after
diagnosis remains as short as 12–15 months [41,42], and only 3–5% of patients survive more than
three years [43]. GBM recurrence is nearly a rule, and, under optimal therapy, recurrent GBM patients
exhibit a median survival of only 5–7 months [44]. Individual tumor cells can be found far from the
primary tumor site, often crossing great distances into the contralateral hemisphere [45]. These cells
cannot be isolated for surgical resection, or easily targeted by irradiation, and thus represent sources
for tumor recurrences [46]. In an attempt to address residual tumor cells, Temozolomide (TMZ) is
included as adjuvant chemotherapy in the current standard of care.
In bright contrast to the relevant progress achieved in terms of outcomes for different cancers, and
to the rapidly growing knowledge of the molecular pathogenesis of GBM, GBM remains a serious threat
and is widely incurable [47]. Indeed, despite current advances in multimodal therapies, including
advanced surgery, radiotherapy, and chemotherapy, and the development of innovative, targeted
therapies, the outcome for patients with GBM is nearly always fatal [48]. Various obstacles hamper
development of effective therapies, including high proliferation rate, intensive angiogenesis, pervasive
tumor cell infiltration, therapeutic resistance, both cellular and molecular heterogeneity, and not least
the lack of a full understanding of the pathobiology of the disease.
4. S1P Level and Metabolism in GBM
Studies performed on human samples demonstrated that a significant decrease of the ceramide
content in human GBM tissues [49] is associated to a marked increase of S1P level, accounting for
about an order of magnitude [50]. Consequently, a highly significant imbalance of the sphingolipid
rheostat occurs, shifting the S1P/ceramide ratio toward S1P by about 20-fold. Moreover, since different
ceramide molecular species exist and execute distinct functions [51], it is relevant that all GBM had
a lower content of the C18 ceramide [50], a species recognized as crucial in promoting cancer cell
death [52]. Noticeably, the S1P/ceramide shift increases with malignancy in tumor tissues and is
directly related to patient survival, indicating that this imbalance is common and represents a similarity
in GBM, independent of the heterogeneous genetic and molecular fingerprint of this cancer. Using a
combination of liquid chromatography and tandem mass spectrometry, differences in the amounts of
cellular S1P were found in human glioma cell lines [53], suggesting heterogeneity of S1P metabolism
and/or export in GBM cells.
To maintain high levels of S1P, GBM exhibits multiple aberrations in S1P metabolism, with different
enzymes contributing to the S1P upregulation. Indeed, different studies indicate that GBM malignancy
is associated with both an increased drive of the cellular pathway that converts ceramide to S1P, and
a decrease of the pathways mediating S1P removal (Figure 1). A key point appears to reside in the
SphK-mediated synthesis of S1P, as substantiated by different findings demonstrating that inhibition
of SphKs (particularly of SphK1) results in the reduction of different S1P-mediated effects (see below).
In particular, several studies reported that human GBM displays a high expression level of SphK1,
and SphK1 mRNA positively correlates with S1P level [50,54–57]. High SphK1 expression has been
found to be correlated with a significant poor prognosis in patients with GBM by some studies [54,55],
but such a relation was not detected in more recent reports [50,57,58]. Despite these contradictory
findings in tumor heterogeneity, the mechanisms underlying SphK1 gene overexpression in GBM
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remain unclarified. An intriguing possibility resides in the very recent findings showing that the long
non-coding RNA named Khps1 (as it is transcribed in antisense orientation to the SphK1) induces SphK1
expression via recruitment of the transcription factor E2F1 to the SphK1 promoter [59]. This hypothesis
appears plausible on the base of recent evidence showing that long non-coding RNAs are key players
in GBM pathogenesis [60], and E2F1 acts as a common regulator of differentially expressed genes in
GBM, despite its genetic heterogeneity [61]. Opposite findings were also reported for SphK2 expression
in GBM. In contrast to SphK1, Abuhusain et al. [50] reported that SphK2 expression in GBM tissues
was 3-fold lower than in normal grey matter. On the contrary, Quint et al. [56] found that the mRNA
expression of SphK2 in primary GBM was 25-fold higher than in normal brain and this enzyme
expression decreases in both recurrent and secondary GBMs. The reason for these opposite findings is
at present unclear. Noting that notwithstanding each SphK isoenzyme has variant isoforms differing
only at the N-terminus [14], the vast majority of the reported studies on SphK expression in GBM do
not specify the targeted specific isoform of the enzyme. Indeed, different unique isoforms of the human
SphK1, differing at the N-terminus (hSphK1a-c) [24,62] and with different intrinsic properties [63],
have been identified. In addition, the SphK2 gene encodes different predicted N-terminal-extended
variants [64] that remain poorly investigated to date. The best-characterized variant is the short isoform
(SphK2-S), which represents the most investigated one in the literature. The large isoform (SphK2-L) is
not expressed in rodents, but appears the predominant form in several human cell lines and tissues,
and thus more important in humans [64].
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Figure 1. Overview of sphingosine‐1‐phosphate (S1P) metabolism and its alterations in glioblastoma 
(GBM). Green: overexpressed/upregulated enzymes;  red: downregulated enzymes. Green and  red 
arrows,  increased  and  decreased  enzyme  activity,  respectively.  The  insert  shows  the  imbalance 
between enzymes involved in S1P formation (green) and degradation (red). 
Functional to the high expression of SphKs is the availability of sphingosine, controlled by the 
interconversion  of  ceramide  and  sphingosine.  The  shift  from  ceramide  to  S1P  increases  with 
. - -
r
, increased and ecreased enzyme activity, respectively. The insert shows the imbalance between
enzymes i volv d i S1P formation (green) and d gr dation (re ).
Functional to the high expression of SphKs is the availability of sphingosine, controlled by the
interconversion of ceramide and sphingosine. The shift from cera ide to S1P increases with increasing
glioma cancer grade [50]. It has been reported that a higher S1P/ceramide ratio contributes to a higher
recurrence rate, implying the S1P signaling is a potent therapeutic target for the treatment of GBM [65].
A recent paper reported that Bcl2L13, the atypical member of the Bcl-2 family overexpressed in GBM,
inhibits ceramide synthase [66]. This would likely result in the reduction of the salvage pathway for
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complex sphingolipid biosynthesis [67], and in facilitating sphingosine use by SphKs. In addition, the
acid ceramidase was found significantly upregulated in GBM specimens, particularly in CD133+ GBM
stem cells (GSCs), and was associated with poor GBM patient survival [50,68,69]. Besides reducing
ceramide, the variations (in opposite directions) of ceramide synthase and acid ceramidase (Figure 1)
appear to concur in favoring the availability of sphingosine as a substrate for SphKs, and thus the
overproduction of S1P in GBM.
In addition to SphK variations, two enzymes involved in S1P degradation are altered in GBM,
further potentiating the metabolic events leading to high levels of S1P in this cancer. First, it was
found that the chromosomal region containing the gene for S1P lyase is deleted in human GBMs [70],
suggesting that S1P upregulation is also favored by a reduction of its catabolism. Second, the S1P
phosphatase 2 (hSPP2), an S1P-specific phosphohydrolase localized to the ER [71], is significantly
downregulated in GBMs, its expression being inversely related to S1P levels and associated with poor
patient survival [50], most likely impairing sphingosine recycling to ceramide at the ER. Consistently,
it was reported that a preferential channeling of sphingosine formed in the lysosomes into S1P
synthesis occurs in GBM cells, whereas S1P is mainly recycled into ceramide in neurons, astrocytes,
and oligodendrocytes [72,73].
Noticeably, the imbalance of the sphingolipid rheostat and related metabolic enzymes was also
reported in low-grade gliomas, which have a relatively good prognosis and prolonged survival
in comparison with GBM. The elevation of the S1P/ceramide ratio was found less pronounced in
low-grade than high-grade malignant tumors [49,50], revealing that this variation is not only common
to all glioma tissue compared to normal brain, but also that its magnitude is directly related to glioma
malignancy. Interestingly, similarly to gliomas, human prostate cancer was reported to exhibit an
increased drive to maintain high S1P levels, with opposite variations of SphK1 (upregulated) and S1P
lyase (downregulated) versus normal tissue, which were all significantly associated with tumor grade
and aggressiveness [74]. Moreover, a high S1P/ceramide ratio, associated with increased expression
of SphK1 and reduced alkaline sphingomyelinase, was found directly related to high malignancy
potential of colorectal cancer [75]. In addition, elevated S1P levels were directly related to SphK1
expression as well as to high malignant grade in human breast cancer [76]. All these findings suggest
that the metabolic aberrations that contribute to sustaining the S1P level, even if different in different
tumors, are functional to cancer malignancy, and independent of individual genetic fingerprints, which
vary greatly in different cancers as well as in individual cancer types.
Concerning brain tumors, it is surprising that, despite the implication of S1P in cancer development
and malignancy, no studies to date have reported on S1P levels, metabolism, and signaling in human
brain cancers other than gliomas.
5. The Tumor Microenvironments and the Specific Features of the GBM Ones
Cancers are not just as an assemblage of malignant cells, but rather develop as aberrant organs,
characterized by intricate components, including various types of non-tumoral host cells and their
extracellular environments [77]. The tumor microenvironment (TME) plays a critical role in tumor
development, and acts as a specialized array of niches with typical traits, where the cross-talk between
the tumor cells and the TME components acts as a key player affecting malignant properties and tumor
progression [78]. Cell-to-cell interactions emerged as crucial contributor to this process, which occurs
via soluble molecular signals by the hypoxic environment of the growing tumor. The TME influence
on cancer progression is a dynamic process, undergoing changes in response to varying environmental
conditions and extracellular signals, along with cancer progression.
GBMs display a high degree of intratumor heterogeneity, and the TME markedly contributes to
this diversity, underscoring the need to understand how GBM cells drive the construction of their own
TME. Increasing evidence supports the GBM microenvironment as an important, complex component
in GBM, which involves communication with, and manipulation of, other brain cells, and tremendously
influences the tumor progression, spread, and treatment resistance [77]. Indeed, GBM tumor cells
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can be exposed to diverse microenvironments, consisting of an array of non-neoplastic cell types,
comprising of resident and infiltrating immune cells, brain endothelial cells (bECs), neurons, astrocytes,
and fibroblasts. These different cell populations can secrete soluble signals, cytokines and growth
factors and extracellular matrix (ECM) components, which enrich the GBM microenvironment with
specific repertoires of signal/regulatory molecules [11,79–81]. These environmental cues create an
inflammatory environment, and steer GBM cell fate through influencing their quiescence, proliferation,
survival, stemness, and invasion, modulating the biological functions of the infiltrating cells to further
support the growth of cancer cells, their invasion, and resistance to therapy.
Of relevance, the TME plays a key role in GSC properties too, leading to an enrichment of
their malignant potential [82]. In the central part of GBM, necrotic areas are present, surrounded by
“pseudopalisading” tumor cells that deal with hypoxia and nutrient starvation, and activate migration
processes in an attempt to escape hypoxia and reach well-vascularized and oxygenated areas [83].
Besides oxygen and nutrient scarcity, these hypoxic niches are highly acidic, thus selecting GBM
cells that are able to withstand hard conditions. Among them, some GSCs can survive, living as
quiescent cells in hypoxic areas. In GSCs, hypoxia inducible factor (HIF) activation occurs, leading to
the expression of metabolic enzymes, ABCTs, and growth factors, and thus potentiating angiogenesis,
immune suppression, and therapy resistance [84–87]. GSCs also reside in perivascular niches, which are
proximal to the invasive tumor edge and close to the disorganized and leaky tumor blood vessels [88],
and an intensive cross-talk between them and ECs promotes angiogenesis, GSC self-renewal, migration,
and survival [89,90].
6. The Cellular Contributors to S1P in the Tumor Microenvironment
In the complex array of signals participating in the TME, accumulating evidence indicates that
S1P represents a key component with multiple cells including tumor ones and the tumor-recruited
brain normal cells, contributing to its enrichment in the GBM microenvironment (Figure 2).
Cells 2020, 9, x  6 of 36 
 
component in GBM, which involves communication with, and manipulation of, other brain cells, and 
tremendously influences the tumor progression, spread, and treatment resistance [77]. Indeed, GBM 
tumor cells can be exposed to diverse microenvironments, consisting of an array of non‐neoplastic 
cell  types,  comprising  of  resident  and  infiltrating  immune  cells,  brain  endothelial  cells  (bECs), 
neurons,  astrocytes,  and  fibroblasts.  These  different  cell  populations  can  secrete  soluble  signals, 
cytokines and growth  factors and extracellular matrix (ECM) components, which enrich  the GBM 
microenvironment  with  specific  repertoires  of  signal/regulatory  molecules  [11,79–81].  These 
environmental  cues  create  an  inflammatory  environment,  and  steer  GBM  cell  fate  through 
influencing  their  quiescence,  proliferation,  survival,  stemness,  and  invasion,  modulating  the 
biological  functions  of  the  infiltrating  cells  to  further  support  the  growth  of  cancer  cells,  their 
invasion, and resistance to therapy. 
Of relevance, the TME plays a key role in GSC properties too, leading to an enrichment of their 
malignant  potential  [82].  In  the  central  part  of GBM,  necrotic  areas  are  present,  surrounded  by 
“pseudopalisading”  tumor  cells  that  deal  with  hypoxia  and  nutrient  starvation,  and  activate 
migration processes  in an attempt to escape hypoxia and reach well‐vascularized and oxygenated 
areas [83]. Besides oxygen and nutrient scarcity, these hypoxic niches are highly acidic, thus selecting 
GBM cells that are able to withstand hard conditions. Among them, some GSCs can survive, living 
as quiescent cells in hypoxic areas. In GSCs, hypoxia inducible factor (HIF) activation occurs, leading 
to  the  expression  of  metabolic  enzymes,  ABCTs,  and  growth  factors,  and  thus  potentiating 
angiogenesis, immune suppression, and therapy resistance [84–87]. GSCs also reside in perivascular 
niches, which are proximal to the invasive tumor edge and close to the disorganized and leaky tumor 
blood vessels [88], and an intensive cross‐talk between them and ECs promotes angiogenesis, GSC 
self‐renewal, migration, and survival [89,90]. 
6. The Cellular Contributors to S1P in the Tumor Microenvironment 
In the complex array of signals participating in the TME, accumulating evidence indicates that 
S1P represents a key component with multiple cells including tumor ones and the tumor‐recruited 
brain normal cells, contributing to its enrichment in the GBM microenvironment (Figure 2). 
 
Figure 2. Cellular types involved in the S1P enrichment of the tumor microenvironment. Stimuli (green
boxes) of S1P synthesis and export in different cells of the GBM microenvironment are shown. Putative
S1P transporters are shown in yellow boxes.
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In order to make possible S1P secretion and its extracellular cross-talk with different cells in the
GBM microenvironments, some important mechanisms of transport and/or communication among those
cells likely play an utmost role. Some ABCTs, including ABCA1, ABCA7, ABCB1 (or P-glycoprotein or
MDR1), ABCC1 (MDR-associated protein-1), ABCC4 (MDR-associated protein-4), and ABCG2 (breast
cancer resistance protein), as well as Spns2 and Mfsd2b, are the known transporters that transfer S1P
through the cell plasma membrane [33,34,36,91,92]. Surprisingly, the role of these transporters in the S1P
secretion by GBM and in the S1P interactions between GBM and non-tumoral cells in the TMEs remains
poorly investigated.
In the following sessions, we review the current knowledge on S1P contribution of the different
tumoral and non-tumoral cells involved in the export of S1P, and thus in its enrichment in the
GBM microenvironments.
6.1. S1P Secretion by GBM Cells and GSCs
Once produced inside GBM cells, S1P can be exported into the extracellular milieu, in an
“inside-out” signaling event crucial for the autocrine and paracrine first messenger action of S1P
through its specific receptors. Edsall et al. [93] initially provided evidence on the extracellular release of
S1P by rat C6 glioma cells, but not by PC12 pheochromocytoma cells, suggesting that not all tumor cells
are equipped with the molecular mechanisms subtending S1P export. Further studies reported that
different human GBM cell lines, including U87MG, CCF-STTG, and T98G, can all constitutively secrete
S1P [50,94–96], underlying the relevance of GBM cells in the secretion of S1P in the extracellular TME.
The treatment of U87MG cells with the SphK1 inhibitor SKI-1a markedly reduced extracellular
S1P, supporting the role of SphK1 in providing S1P for export [50]. Importantly, different signaling
mediators strictly connected to GBM malignancy can increase the basal expression and activity of
SphK1. These stimuli include basic fibroblast growth factor (bFGF), epidermal growth factor (EGF),
vascular endothelial growth factor (VEGF), tumor necrosis factor α (TNF-α), platelet-derived growth
factor (PDGF), insulin-like growth factor binding protein-3 (IGFBP3) [10,97–103], and, not least, S1P
itself [104,105]. These molecules induce a rapid and transient activation of SphK1, its subsequent
translocation to the plasma membrane, and export of newly synthesized S1P, and can exert long-term
effects by enhancing the SphK1 expression [106,107]. More than 30 years ago, Libermann et al. reported
that the EGF receptor is overexpressed and constitutively activated in GBM [108]. Nowadays, this
feature is considered an important event in the pathogenesis of a subset of GBMs. EGF stimulates
SphK1 activity and induces its translocation from the cytosol to the plasma membrane through
sequential activation of c-Src and PKCδ [99,109]. Moreover, it was found that interleukin 1 (IL-1), a
pro-inflammatory cytokine secreted by GBM cells in relevant amounts [110], upregulates SphK1 at the
transcription level, resulting in a correlation between its level and that of SphK1 in GBM cells [111].
In human GBM cells, IL-1 induces transcription of SphK1 by a novel activating protein 1 element
located within the first intron of the SphK1 gene, which can be blocked by inhibition of JNK [111].
Hypoxic stress also increases the expression of SphK1 in GBM cells, through an increase in HIF-2α
activity that binds to the promoter of the SphK1 gene, leading to increases in not only intracellular
but also extracellular S1P [112,113]. Of interest, the SphK1/S1P-signaling pathway emerged as a
regulator of HIF-2α expression in multiple cancer cells, including GBM ones [114], suggesting a
positive feedback loop between SphK1/S1P and HIFs in response to hypoxia. Similar to the HIFs, the
LIM-only transcription factor LMO2, an important regulator of angiogenesis that promotes angiogenic
traits in GSCs [115], binds to the SphK1 gene and increases the expression of SphK1 protein [116].
Despite these numerous reports underlying the role of SphK1 in S1P export by GBM cells, very
recently Neubauer et al. [117] demonstrated that SphK2 plays a role too. In particular, it was found
that SphK2 interacts with the cytoplasmic DYNC1I1-containing dynein complex, and this interaction
appears to facilitate transport of SphK2 away from the cell periphery. In GBM cells, a dramatic
downregulation of DYNC1I1 correlated with poorer patient survival, and paralleled with SphK2
localization to the plasma membrane and formation of extracellular S1P [117],
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It should be added that both SphK1 and SphK2 are secreted by some normal and tumor cells
as a component of shed vesicles [23,118–120], likely indicating that SphKs localized in these vesicles
cause sustained extracellular S1P production. However, the role of vesicle-mediated formation of
extracellular S1P in the GBM microenvironment remains largely unknown.
In the U87MG cell line, the ABCA1 transporter, which facilitates S1P efflux in astrocytes, was
found involved in the S1P efflux, thereby contributing to inside-out signaling [121]. ABCA1 expression
in this GBM cell line is potently induced by 25-OH-cholesterol [121], a natural oxysterol synthesized
and secreted by GBM cells [122], suggesting that oxysterol synthesis provides an autocrine signal that
enhances ABCA1 expression and S1P export from GBM cells.
Further relevant findings refer to S1P metabolism in GSCs, the small population of GBM cells
crucial for its malignancy. We recently reported that GSCs are equipped with an efficient molecular
machinery that allows them not only to rapidly form S1P, but also to efficiently export it [95,123].
Importantly, GSCs recently emerged as the cells with the greatest synthesis and secretion of S1P in
GBM, the amount of extracellular S1P provided by GSCs accounting for about one order of magnitude
higher than that by GBM cells [95]. It is worth noting that, despite similarities between neural
stem cells and GSCs [124], GSCs appear to possess the unique ability to export S1P and enrich their
extracellular milieu with S1P, as neural stem cells are incapable of this export [125]. The efficiency of
S1P export by GSCs is strictly dependent on the availability of its substrate sphingosine [123], which
can be released from necrotic cells. The enrichment of GSCs in the perinecrotic niche of GBM [126]
suggests that S1P biosynthesis and release occur very rapidly and to a high extent in this niche,
providing these cells with a favorable microenvironment. Importantly, the proliferative and stemness
properties of GSCs relate to a gain in extracellular S1P, paralleled by a downregulation of intracellular
ceramide levels due to increased metabolic flux to complex sphingolipids [9,123]. Thus, an imbalance
of the sphingolipid rheostat, with the S1P domination in the GSC niches, occurs, and provides an
advantage to the malignant qualities of GSCs. Moreover, the investigation of the effect of EGF and
bFGF, recognized autocrine signals in GSCs, revealed that the constitutive S1P secretion by GSCs is
proliferation-dependent, and significantly enhanced by the presence of these growth factors [123]. Up
to now, the mechanism underlying S1P export by GSCs is unknown. It should be noted that different
ABCTs, known as transporters of S1P through the cell plasma membrane, and particularly ABCB1,
ABCC1, and ABCG2, are highly expressed in GBM cells, and particularly in GSCs [127–129]. Their
expression is correlated with GBM aggressiveness [130], suggesting their possible involvement in the
S1P export from GSCs/GBM cells.
Despite the influence of GBM interactions with GSCs emerging [131,132], up to now it is unclear
whether GBM cells contribute to S1P secretion by GSCs and/or vice versa.
6.2. S1P Secretion by Non-Cancer Cells Recruited in the GBM Microenvironment
The TMEs in which GBM cells develop and grow largely contribute to its heterogeneity. GBM
microenvironments contain an array of non-neoplastic cells, including infiltrating and resident
immune cells, vascular cells, and other glial cells. GBM cells subvert normal brain cells to create
microenvironments that contribute to crucial GBM properties and favor tumor success. Indeed,
GBM cells recruit different normal brain cells, such as astrocytes, innate immune cells, and ECs, and
change their phenotype, inducing them to modify the GBM microenvironments with pro-tumoral
signals [133–136]. In the following sections we overview the cross-talk between GBM cells and
normal brain cells, and focusing on the contribution of non-tumoral cells to the S1P level in the
GBM microenvironments.
6.2.1. Microglia and Macrophages
Two types of immune cells, called tumor-associated macrophages (TAMs), including intrinsic
microglia, and peripheral-recruited macrophages, represent the majority of the non-neoplastic cells
in GBM [137]. Microglial cells are recruited at the tumor site by GBM-secreted chemoattractant
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factors [138,139], while blood-derived macrophages accumulate in GBM through the breakdown of
the blood–brain barrier (BBB) [140]. Both these TAMs can release a wide array of growth factors
and cytokines in response to factors produced by GBM cells, which create a supportive stroma for
neoplastic cell expansion and invasion, and facilitate GBM progression [88,141].
Different investigations performed on microglial cells demonstrated an important role of S1P in the
pathogenesis of inflammation [142–145], including neuroinflammation [146]. Both macrophages and
microglial cells are able to secrete S1P extracellularly; inflammatory stimuli, such as lipopolysaccharide
(LPS), upregulate SphK1 expression on the plasma membrane in these cells and significantly increase
S1P secretion from microglia [147–149]. Microglia/macrophages express different ABCTs shown
to mediate the S1P efflux, including ABCB1, ABCC1, and ABCG2 [150–152], and their expression
changes after LPS activation [150]. In addition, a very recent report showed that the S1P transporter
Spns2 is expressed and functions as a transporter of S1P export from microglia, promoting microglia
pro-inflammatory activation in vitro and in vivo [153].
Despite the current knowledge on S1P from TAMs in GBM being limited, TAMs are among the
cell types that can contribute to enriching the GBM microenvironment with S1P, and to promote GBM
progression (see below).
6.2.2. Endothelial Cells
GBM has highly abnormal and exuberant angiogenesis, the formation of aberrant tumor
vasculature representing a key event in its growth and malignancy [76]. Indeed, endothelial activation
significantly contributes to the GBM microenvironment and acts as a critical regulator of GBM
progression [77].
Interestingly, SphK1 is overexpressed in ECs from brain tumors, and S1P stimulates ABCB1
expression and transport, suggesting that SphK1 and S1P could contribute to the multidrug resistance
phenotype in brain tumor-derived ECs [154]. Very recently, we reported that bEC lines, as well as
primary bECs derived from different GBM patients, exhibit the capacity of spontaneously secreting
S1P into the extracellular environment in significant amounts [96]. A small fraction of S1P is produced
in the bEC-conditioned medium [96], suggesting that S1P may be also produced extracellularly by an
extracellular SphK, as it occurs in human umbilical vein ECs [23]. Most importantly, co-culture with
human GBM cells induces overexpression, plasma membrane translocation, and enhanced activity of
SphK2, which leads to a potent stimulation of S1P export by different bECs [96]. Therefore, GBM-EC
co-culture induces an enhancement of S1P synthesis and export by bECs, this last possibly through
ABCB1 or Spns2 [155]. These findings indicate that bECs are able to increase the rate of S1P production
and release in response to GBM co-culture, suggesting they stimulate GBM cells to produce diffusible
factor(s) that favors their “inside-out” S1P signaling in the absence of cell-to-cell contact.
6.2.3. Neurons and Astrocytes
Previous studies demonstrated that primary cultures of cerebellar and hippocampal neurons
express SphK1 and have the capacity to secrete S1P in the extracellular milieu [156,157]. This secretion is
potentiated by neuronal depolarization, PKC activation, and by the glutamate neurotransmitter. Upon
stimulation, SphK1 was shown to translocate to the plasma membrane and produce S1P for autocrine
S1P receptor signaling [156,157]. It was reported that exogenous S1P elicits glutamate secretion, and
potentiated depolarization-evoked secretion from neurons [156], suggesting that a depolarization/S1P
secretion cycle occurs. Despite the detrimental effects of GBM progression on neuron survival and
function [158,159], the influence of GBM on S1P production by the neuronal population remains
unknown. Interestingly, GBM has the ability to release glutamate in the nearby environment [160], and
a clinical study involving GBM patients found peritumoral glutamate levels 100-fold higher than those
in an uninvolved brain [161]. Thus, it appears likely that neuronal proximity to GBM cells may favor
S1P enrichment in GBM microenvironments.
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Different is the knowledge about astrocytes, which emerged as important cellular sources of S1P in
the central nervous system (CNS), and which are potentially involved in the GBM microenvironments.
Indeed, these cells are able to efficiently export S1P [156], and bFGF, a crucial factor in GBM progression
and stemness, as well as in GBM resistance to anti-VEGF therapy [162–164], was found to act as a
potent stimulus of S1P export [156]. Of note, the ABCA1 inhibitor glyburide was reported to induce an
accumulation of intracellular S1P and exogenously added S1P partially restored astrocyte proliferation
in the presence of this inhibitor [156]. These and other findings [165] appear to support a critical role
for ABCA1 in mediating this export. Moreover, very recently, Dréan et al. [130] showed that ABCG2 is
highly expressed by astrocytes, suggesting its possible involvement in S1P efflux from these cells.
7. S1P Role in Cancer Hallmarks
As a malignant tumor, GBM exhibits hallmark capabilities that are crucial to cancer
phenotypes [166]. Hallmark characteristics of GBM include uncontrolled proliferation, invasiveness,
stemness, intense angiogenesis, and death resistance, and account for GBM’s resistance toward
radiotherapy and chemotherapy and poor prognosis. Very recently, enabling replicative immortality,
inducing angiogenesis, reprogramming cellular energetics, and evading immune destruction emerged
as the challenge to find similarities in GBMs and as the most promising GBM hallmarks for clinical
impact [167]. Of relevance, S1P in the GBM microenvironments has been implicated in regulating
key properties underlying GBM malignancy and deadly features [9,10], participating in the different
mechanisms known to sustain the hallmarks of cancer (Figure 3).
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Despite the suggestion that S1P may function as an intracellular signal [4,168], most of its actions
in cancer c lls occur through its acting as a high-affinity agonist at its five known G protein-coupled
re epto s, and downst eam activa on of their signaling pathways [169]. S1P receptors ar a family of
G protein-coupled receptors belonging to the endothelial differentiation gen (EDG) receptor family,
which are involved in the signaling of the lysophosp o pi s S1P and lysophosphatidic a id (LPA) [170].
The S1P1–5 members of this family, which are specific for S1P, are able to induce multiple biological
pathways strictly related to cancer biology [169]. It was shown that different human GBM cell lines
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and GBM specimens express the genes of S1P1–3 and S1P5 receptors. Increased levels of S1P1, S1P2,
and S1P3 were observed in GBM tissue specimens, and signaling of S1P1 and S1P2 were markedly
correlated with patient survival rates [57]. Despite Yoshida et al. [58,171] reporting that S1P1 expression
is downregulated in GBM specimens, which enhances tumor cell proliferation and correlates with
shorter survival of GBM patients, recent investigations demonstrated an inverse correlation between
S1P1 expression and GBM patient survival [50,56,57]. Whether these opposite findings depend on the
heterogeneity of GBM or experimental conditions remains to be clarified.
S1P1–3 are linked to several, often interconnected signaling pathways, including mitogen-activated
protein kinase (MAPK), c-Jun N-terminal kinase (JNK), extracellular signal-regulated (ERK/MAP)
kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), phospholipase C (PLC), phospholipase
D, and other downstream mediators [1,22,168]. S1P can stimulate diverse signal transduction pathways
in different cell types, as well as within the same cell, depending on the expressed S1P receptor
pattern, as well as their differential coupling to different G proteins. S1P1 is known to be coupled
exclusively to Gi protein, leading to cAMP reduction and activation of Ras, MAPK, PI3K, Akt, and
PLC pathways. Both S1P2 and S1P3 are coupled to Gi and G12/13 proteins, and activate Ras, MAPK,
PI3K, serine-threonine kinase Akt, PLC, and Rho-dependent pathways. G protein-coupling properties
of S1P4 and S1P5 are less clear at present. They couple to Gi and G12/13, to activate Rho-dependent
pathways, and mainly influence cell motility and migration.
In addition to transducing S1P signaling, the G protein-coupled S1P receptors have been implicated
in signal amplification of a variety of growth factor receptors, via receptor transactivation [172]. Moreover,
transactivation of S1P receptors by growth factors may also occur [173,174]. This transactivating cross-talk
likely results in the potentiation of downstream signaling pathways, and thus of cell malignancy.
Very recently, El Buri et al. [175] have identified a new novel mechanism by which S1P regulates
the TME. The authors found that, like the SphKs, the S1P2 receptor was released through exosomes
into the conditioned medium from a breast cancer cell line, and induced robust ERK1/2 activation and
proliferation of fibroblasts. Despite this interesting finding, to date it remains unknown if the release of
exosomal S1P receptors occurs in GBM and/or other cancers, and contributes to their properties.
The features of S1P-signaling pathways in cancer, including GBM, are complex and interconnected
and, through autocrine and paracrine signaling as well as overexpression of S1P receptors, lead to high
cell responsiveness. In the following part of this paper, we describe the actual knowledge on the S1P
signaling that pertains to their specific involvement in GBM hallmarks.
7.1. S1P in the Cancer Microenvironment Promotes Sustained Proliferation
Among the different properties of GBM, there is a highly proliferative potential, and the tumor
microenvironment is essential to control proliferation. Of relevance, excessive growth factor signaling
is a crucial component of GBM malignancy, including the abundance of EGF, bFGF, and VEGF [80].
The signaling of all these factors involves S1P as mediator, as they induce a rapid and transient
activation of SphK1, its translocation to the plasma membrane and S1P export, and can exert long-term
effects by enhancing SphK expression. In particular, several reports demonstrated that SphK1 has an
important growth-regulatory role in different cancer cells, and plays a crucial role in the mitogenic
action of S1P in human GBM cells, too. Indeed, SphK1 inhibition results in growth arrest of GBM cells
both in vitro and in vivo [54,55,176,177]. The highly proliferative areas of GBM are close to the central
necrosis, where hypoxia is at its highest expression [178], and this environment promotes SphK1 and
S1P export (see above). Among different growth factors, IGFBP3 is overexpressed in GBM [102], and
its expression is associated with poor patient outcome [179]. IGFBP3 functions as a potent regulator of
GBM cell proliferation, and its action as a tumor promoter occurs through increasing SphK expression
and S1P formation [180]. Notably, S1P has been reported to stimulate the production and secretion of
EGF, PDGF and VEGF [181], as well as to transactivate EGF/IGF receptor-signaling pathways, leading
to enhanced GBM cell proliferation and tumor growth [172]. Thus, S1P-induced transactivation of
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these receptors appears to constitute an efficient switch to integrate rapid G protein-dependent signals
into long-term cell proliferation.
SphK1 was also found to be involved in the proliferative effect of IL-1, which upregulates this
kinase [111]. Moreover, SphK2 knockdown was found to inhibit GBM cell growth more potently than
SphK1 knockdown [54], suggesting that both SphKs can participate to promote GBM cell growth.
Consistently, both SphK1 and SphK2 isoforms were found involved in the proliferation of GBM cells
in hypoxic conditions [113]. The proliferative effect of the activation was reported to occur through
ERK-dependent activation for SphK1 and ERK-independent activation for SphK2, and the cell cycle
was arrested in G2⁄M phase or in S phase, respectively [113].
The proliferative role of extracellular S1P in GBM is further substantiated by several reports
demonstrating that human GBM cells respond mitogenically to nanomolar concentrations of
S1P [57,96,121,182], and that extracellular S1P antagonized the inhibition of cell proliferation induced
by inhibition of the S1P transporter ABCA1 [121]. The proliferating effect of S1P was found to
involve its binding to, and activation of, different S1P receptors, including S1P1–3 and S1P5, which
are expressed in different GBM cell lines and human GBM specimens [54,57,58,96,171,182]. The S1P
binding to all these receptors is able to affect GBM proliferation due to the ability of these receptors
to activate Gi (all S1P receptors) and/or G12/13 (S1P2, S1P3 and S1P5) [121]. The activated signaling
pathways lead to the activation of ERK/MAP kinase, through both PI3K-dependent and independent
pathways [182,183]. Through the stimulation of ERK/MAP kinase, S1P1 induces the expression of
bFGF [184], and it was shown to exert a potent effect on GBM cell proliferation due to its high potency
for ERK activation [185]. In agreement, SphK1 was shown to contribute to EGF-induced GBM cell
growth by enhancing activation of ERK signaling [186]. Interestingly, we recently reported that brain
ECs and GBM-derived ECs co-cultured with GBM induce increased expression of S1P1 and S1P3 in
GBM cells, which promote S1P-induced proliferative properties in GBM cells [96].
It was shown that the overexpression of S1P5, opposite to that of S1P1–3, decreases cell proliferation
in GBM cells [56], suggesting that a balance among different S1P receptors participates in the control of
GBM proliferation.
Notably, the capacity for extensive proliferation and self-renewing is crucial not only in GBM cells,
but is also a key determinant of GSCs [187]. Using GSC lines derived from human GBM specimens with
different proliferative indexes, we found that S1P promotes GSC proliferation, cell cycle progression,
and stemness phenotypic profile [123]. In addition, the export of S1P was enhanced in the cells
exhibiting a high proliferative index, suggesting that S1P may act as an autocrine signal to maintain a
pro-stemness environment, and favoring GSC proliferation and stem properties [123]. Interestingly,
besides inducing the growth pattern of GSCs, S1P induced different stem cell markers in GSCs, thus
enhancing their stemness phenotype [123]. Since S1P was unable to induce the expression of stemness
markers in non-stem primary GBM cells, it appears that the S1P-promoting stemness resides in its
ability to favor the selective expansion of GSCs.
The signal transducer and activator of transcription 3 (Stat3) is constitutively activated by
phosphorylation in GSCs, promotes GSC proliferation, and is indispensable for GSC-induced tumor
formation [188]. Of relevance, Stat3 has S1P1 as a transcriptional target, and, in turn, S1P1 signaling is
required for persistent activation of Stat3, thus creating a positive feedback loop that fuels the growth
of a range of cancers, including GBM [189]. Hirata et al. [190] found that in GSCs and in several types
of cancer stem cells, activation of Gi-coupled S1P3 by S1P results in the induction of proliferation
through binding and activation of Notch signaling, a key stem cell pathway. Moreover, a very recent
study reported that, in both GBM cells and GSCs, the response to S1P stimulation through G12/13
coupled receptors involves the activation of RhoA, which results in divergent signaling pathways, both
required for the nuclear accumulation of the transcriptional coactivators MRTF-A and YAP, as well as
for cell proliferation [191]. S1P stimulates cell proliferation only when both MRTF-A and YAP can
be activated [191], implicating that more than a single signaling pathway needs to be turned on to
increase the rate of GBM proliferation.
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Overall, S1P promotion of GBM cell and GSC proliferation appears to occur as a complex,
dysregulated and fail-safe mechanism, implicating the involvement of different receptors and multiple
signaling pathways, including divergent molecular interactions (Figure 4).
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phospholipase C (PLC), and phosphoinositide 3-kinase (PI3K) pathways; and ii) G12/13 may promote
actin polymerization through RhoA. Following the activation of downstream signaling pathways, S1P
prompts the activation of different transcription factors, leading to the regulation of different genes
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7.2. S1P in the Cancer Microenvironment Promotes Invasive Behaviour
GBM is an extremely aggressive tumor which exhibits an exceptional ability to invade the
surrounding par nchyma, and widely infiltrates normal brain, typically disseminating along blood
vessels or nerve fibers, nd reaching bra n regions ny ce timeters away from the main tumor
ma s [39,192]. The highly infiltrative nature f GBM makes complete surgical resect on with clean
margins nearly impossible, and gives rise to recurrence, a process that occur in almost all GBM p tient
d spite aggre sive surgical resection and ch motherapy [39]. Moreover, although metastatic GBM i
rarely observed, GBM can spread hem togenously [193], and numer us cases of extracranial metastasi
in GBM patients are reported [194]. In additi n, there is accumulating evidence th t current therapeutic
odalitie , i cluding nti-angiogenic th rapy and radiotherapy, can enhance glioma invasiveness.
GBM cells secrete several factors th t prom te their motility th ough autocrine/paracrin
signaling [195]. Different studies have implicated SphK/S1P signaling in enhancing cancer cell
migration, invasion and metastasis, the effects f S1P varying between different cancers and even
among different cells of the same cancer [196]. Studies on cell migration demo strated that different S1P
receptors exert opposite eff cts on GBM cells. Indeed, S1P1 a d S1P3 signal migratory r spo ses and
plify those exerted by other growth factors, whereas S1P2 signals inhibition f growth factor-evoked
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migration [185,197]. The possible reason of this antagonistic effect appears to reside in the fact that
S1P1 and S1P3 stimulate the small GTPase Rac, whereas S1P2 inhibits it [198]. Since the S1P2 activation
of Gi is by far less efficient than that of S1P1 and S1P3, it was hypothesized that the robust activation of
the G12/13-Rho pathway by S1P2 likely masks its Gi-mediated Rac stimulation, resulting in inhibition
of cell migration [199].
Opposite to the negative effect of S1P2 on cell migration, the activation of all S1P1–3 receptors
results in a potent increase in GBM cell motility and invasiveness of different GBM cell lines. In particular,
S1P emerged as a key signal in the regulation of GBM invasion, being able to stimulate different
events involved in this complex process, including reduction of cells and of extracellular matrix
(ECM) adhesion, cytoskeletal remodeling, matrix metalloprotease (MMP) secretion, and then ECM
degradation (Figure 5).
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Figure 5. Effect of S1P on GBM invasivity. The interaction of S1P with its receptors results in the
activation of different signaling pathways, and enhanced gene and protein expression, leading to
detachment (at the trailing edge) and attachment (at the leading edge) of the migrating cell, with
stimulation of the extracellular matrix degradation favoring and cell invasion.
Overall, G protein signaling of the S1P1-3 subtypes results in: (1) Rac activation [198], which
regulates cell morphology and actin dynamics, and stimulates cell squeezing through the narrow
extracellular spaces that are typical of the brain parenchyma; (2) increased secretion of the matricellular
protein CCN1/Cyr61 that, once secreted, binds to integrinαV-β3 to enhance ECM adhesion [185,200,201];
(3) activation of the signaling cascades MEK1/2, PI3-kinase/AKT1 and Rho-kinase, which leads to
enhanced gene and protein expression of the plasminogen activator system proteins, including the
urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1), and a receptor
for uPA (uPAR) [57,183,202].
As for the potent induction of GBM cell invasiveness by S1P, the upregulation of the pro-invasive
molecule CCN1, neurogulin-1 (NRG-1), uPA and its receptor has been shown to be involved [185,200,203].
Matriptase, upregulated through S1P-receptor signaling, is also secreted, and activates uPA that induces
MMP activation, leading to the activation of plasminogen to plasmin. On its turn, plasmin, as such, or by
activating MMPs, promotes the degradation of extracellular matrix and cellular invasiveness (Figure 5).
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Another very important signal in the migration and invasion of GBM cells by S1P is Ca2+
mobilization [204,205], a signaling event linked to most S1P receptors [206,207]. The Ca2+ gradient
in GBM cells allows them to move in a specific direction, and activates calpain 2, a cysteine protease
important for the invasion of GBM cells within the dense microenvironment of the brain [208]. S1P5
was found as responsible for stimulation of PLC-Ca2+ system in C6 glioma cells [184], and S1P2 later
appeared as the most likely factor responsible for PLC activation and Ca2+ release in GBM cells [197].
Of interest, the competitive inhibition of the microsomal glucose-6-phosphate transporter (G6PT),
which can enhance Ca2+ sequestration in the ER [209], was shown causing a downregulation of
S1P-induced cell migration [210]. Moreover, it was found that gene silencing of not only the G6T but
also the membrane-type 1 MMP (MT1-MMP) decreased the extent of S1P-induced Ca2+ mobilization,
unrevealing these signaling pathways that are required in GBM cells for efficient Ca2+ mobilization,
and invasive effects in response to S1P [204].
It is important to highlight that different signaling pathways can influence the S1P-dependent
GBM cell migration and invasion. For instance, EGF and IL-1 signaling pathways may enhance
S1P-dependent expression of PAI-1 and uPAR [99,201]. In addition, PDGF-induced GBM chemotaxis
is dependent on S1P, which in turn activates the transient receptor potential channel TRPC1, leading to
the entry of Ca2+ and increased cell invasivity [211].
Finally, it emerged that S1P is relevant also in the potent invasive properties of GSCs. In particular,
a population of GSCs isolated from the U87MG cell line exhibited an increased migratory response
to S1P compared with parental cells, and combined regulation of S1P/LPA-mediated signaling and
MT1-MMP are involved in the invasive properties of GSCs [212]. In addition, the high invasive
potential of GSCs was found correlated with the high expression of S1P1 [200,212].
7.3. S1P in the Cancer Microenvironment Promotes Death Resistance
In different cancer cells, S1P acts as a key actor both in promoting survival pathways and in
antagonizing the players of death signaling, including those involving ceramide. It is widely recognized
that the balance between ceramide and S1P levels in GBM cells plays a crucial role in determining
cellular fate, and leads to cell death when ceramide prevails or to cell survival when S1P levels are
increased. The dysregulation of the ceramide/S1P rheostat appears crucial in the death-resistance
features of GBM [9]. There is strong evidence demonstrating the role of ceramide as a death-inducing
signal, involved in the toxic effects of chemotherapeutic drugs and radiations, as well as that of S1P
in promoting cell survival in different cancer cells [6,213]. To antagonize autophagic/apoptotic death
induced by chemotherapeutic drugs, chemotherapy-resistant GBM cells are able to maintain reduced
levels of ceramide [214]. In addition, the upregulation of S1P represents a key strategy to survive and
to enhance their death resistance properties of GBM cells, GSCs and human GBM tumors [9]. Indeed,
GBM cells and GSCs use S1P to maintain and promote their survival, even when submitted to toxic
treatments, such as radio-chemotherapy.
S1P plays a very important role in apoptosis, and the activity of SphK1 was found directly related to
the survival of cancer cells and acquisition of replicative immortality, in a process termed ‘non-oncogenic’
addiction [215]. Several studies support a key role of SphKs in the promotion of S1P-induced survival
in GBM, and SphK inhibition/genetic ablation sensitizes GBM cells to chemotherapeutics, and slows
GBM growth in mice. A pivotal study reported that SphK1 expression correlates with poor survival
of patients with GBM [54], and the following investigations revealed the importance of this enzyme.
In particular, it was found that SphK1 inhibition: (1) leads to cell death by inducing apoptosis of
human GBM cells and xenografts, and reduces survival in orthotopic GBM [72,177]; (2) sensitizes
GBM cells, and different cancer cells, to several cytotoxic drugs [216]; (3) is effective in potentiating
the cytotoxicity of both TMZ and radiation therapy in various human GBM cell lines [217,218]; and
(4) induces apoptosis and inhibits colony formation in TMZ-resistant GBM cells [219]. Of relevance,
recent studies on GBM irradiated cells revealed that S1P is upregulated, and SphK1 gene significantly
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induced following radiation, suggesting that S1P links to radio-resistance and increased aggressiveness
of irradiated GBM cells [69,220].
The mechanisms underlying the pro-survival properties of S1P mainly include signaling pathways
that result in the inhibition of apoptosis and/or the induction of protective autophagy [9]. S1P-mediated
protection from apoptosis appears to occur primarily through Gi-mediated activation of PI3K/Akt/eNOS
signalling, and ERK and p38MAPK have been implicated too [221]. S1P-mediated inhibition of
apoptosis further involves inhibition of cytochrome c release, activation of caspases, and activation of
the stress-activated protein kinase JNK.
The relevant role of S1P in GBM survival is strengthened by accumulating reports on S1P
antagonists as potential targets for cancer therapies. The survival effect of S1P in GBM cells has been
related to the activation of different survival pathways, and among them the PI3K/Akt signaling
pathway that is involved in the pathogenesis of GBM and plays a crucial role in conferring GBM
resistance to cytotoxic treatments [222–224]. S1P can induce robust Akt activation, most probably
through a Gαi signaling pathway, which in turn signals to a variety of key downstream molecules,
finally suppressing cell death and promoting cell survival [225]. Indeed, targeting SphK1 in GBM
cells with SK1-I rapidly reduced Akt phosphorylation, inhibited JNK, and finally reduced death in
GBM cells in vivo [177]. Through the overexpression or downregulation of SphK1 in GBM cells, it
was shown that S1P suppresses apoptosis induced by radiation and chemotherapeutic drugs via
Akt activation, subsequent inactivation of FOXO3a and of Bim, and finally downregulation of the
proapoptotic Bcl-2-like protein 11 (Bim) [226]. Additionally, and consistent with the survival role of
S1P, the S1P receptor antagonist FTY720 induces apoptosis in GBM cells [227,228].
Opposite to the S1P-mediated activation of Akt, ceramide acts as a potent inhibitor of this signaling
pathway. Notably, Akt stimulation in GBM cells also promotes the ER–Golgi trafficking of ceramide
and its use for the synthesis of complex sphingolipids, leading to a reduction of ceramide levels and
inhibition of ceramide-induced apoptotic and non-apoptotic cell death [229]. Thus, the S1P-promoted
Akt activation results not only in the promotion of survival signaling pathways, but also in the
inhibition of ceramide-induced cytotoxicity. It is worth noting that that the bioflavonoid luteolin,
recently proposed as an effective anticancer agent for different human neoplasia including GBM [230],
exerts a potent cytotoxic effect by increasing ceramide and downregulating S1P and Akt activation [231].
On this basis, it is likely that the high levels of S1P in human GBM might contribute to the intrinsic
resistance of GBM to cytotoxic treatments also by inducing low ceramide levels. In support, ceramide
levels in GBM samples inversely relate to tumor progression and survival of GBM patients [49,50].
Currently, it is assumed that GBM recurrence results from GSCs, which are intrinsically radio- and
chemo-resistant, highly invasive, enriched after radiotherapy, and directly associated with poor patient
prognosis [136]. Different reports found that S1P plays a key role in GSCs resistance to TMZ [95].
Indeed, the inhibition of S1P biosynthesis made GSCs sensitive to TMZ, and exogenous S1P, alone or
in combination with TMZ, was able to revert the cytotoxic effect of TMZ–SphK inhibitor co-treatment,
promoting GSC survival. Annabi et al. [212] reported that GSCs are much more responsive to
extracellular S1P than their parental GBM cells, with differences in S1P-receptor expression contributing
to this feature. Since S1P1 expression is increased in GSCs from U87MG GBM cells, and promotes
cell survival in cultured cells and in a murine model of intracranial GBM [212], it appears reasonable
that S1P1 might be involved in the pro-survival effect of extracellular S1P in TMZ-treated GSCs.
In support, it was reported that administration of the functional S1P antagonist FTY720 to nude mice
led to downregulation of S1P receptors, induced apoptosis in GSCs, and was synergistic with TMZ in
promoting cytotoxicity [232]. Of relevance, the apoptosis induced by inhibiting SphKs was shown to
be highly effective, and to specifically target GSCs [220], known as resistant cells to the standard GBM
chemotherapy agent TMZ.
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7.4. S1P in the Cancer Microenvironment Promotes Immune-Evasion
Among the different non-neoplastic cells of the GBM microenvironments, cells of the immune
system, and especially TAMs, play a critical role in the regulation of tumor malignancy [233]. These
cells are the dominant non-tumoral population, accounting for 30%–40% of the cells in the tumor, are
inversely correlated with patient survival [234,235], and engage in reciprocal interconnections with
tumor cells to promote GBM growth, progression, and invasion [236]. Consistently, in both animal
xenografts and surgical resections, the invasive front of GBM, where GSCs reside, contains abundantly
infiltrating TAMs [237], and in in vivo GBM models, depletion of microglia/macrophages significantly
reduces tumor growth [238].
Microglia and macrophages can possess highly diverse phenotypic and functional heterogeneity
by polarizing to either M1 or M2 sub-types, which are representative of anti- and pro-inflammatory
phenotypes. It is believed that tumor-associated macrophages are mainly M2 macrophages, and more
likely contribute to tumor growth, rather than exerting effective antitumor protection [239], and M2
abundance is associated with poor prognosis for patients with different tumors including GBM [240,241].
Microglia/macrophages within GBM appear to initially participate in tumor surveillance as M1 type,
but are then subverted by GBM to adopt M2 anti-inflammatory phenotypes, and subsequently promote
immunosuppression, tumor angiogenesis, and invasion [242]. TAMs can also secrete immunosuppressive
factors, such as IL-4, IL-10, and TGF-β1, which in turn polarize M1 cells into the M2 type, which suppresses
antitumor-immune responses [243]. In further support, a recent immunogenomic analysis of 33 distinct
cancer types classified GBM among tumors with a greater range in leukocyte fraction compared to other
cancer types, with a prominent M2-like macrophage signature, and a high anti-inflammatory macrophage
response [244].
Several studies have identified an essential role for S1P and its receptors in immune
responses [143,146,245]. Microglial cells and macrophages express all five S1P receptors (S1P1–5), and
their expression varies according to the activation state of these cells [148,246,247]. S1P1 receptors,
highly expressed on naïve macrophages, are decreased in both M1- and M2-polarized cells, while S1P4
is reduced only in M1-polarized cells [247]. S1P induces monocyte migration in a receptor-specific
fashion, with S1P1 and S1P3 receptors being involved in the migration of pro-inflammatory M1 and
anti-inflammatory M2, respectively [248–250]. Because the migration potential of M1 is higher than
that of M2 macrophages, it has been suggested that the ratio between S1P1/S1P4 receptors orchestrates
macrophage migration [247]. The elevated S1P content within GBM tissue [50] and the reduced
circulating level of S1P in GBM patients [251] might foster monocyte migration from the peripheral
blood into the tumor, and TAM formation.
Different studies support an important regulatory role of SphK1 in the activation of the
microglia/macrophages by pro-inflammatory factors [252]. Pro-inflammatory factors, such as LPS
and transient cerebral ischemia, result in an increase in the expression and activity of SphK1, and
consequently in an increase in the production of S1P [148,149,152,252]. S1P signaling in TAMs leads
to increased cellular proliferation, and enhanced production of different pro-inflammatory cytokines
(such as TNF-α and IL-1β and IL-17) and nitric oxide, and this signaling is inhibited by SphK1 inhibition
or gene knockout of this enzyme [149,253]. S1P1–3 receptor subtypes were identified as relevant in
S1P signaling in transient cerebral ischemia [253–256]. In addition, S1P regulates M1/M2 polarization
toward brain damage as a pathogenesis of cerebral ischemia. In particular, in activated microglia
of post-ischemic brain, M1 polarization occurs mainly through S1P1, and suppressing S1P1 activity
increased mRNA levels of M2 polarization markers [257].
Conversely, Hughes et al. [258] found that during acute inflammation S1P is able to suppress the
M1 macrophage polarization through S1P1-Gi-coupled signaling and inhibition of NF-κB. In addition,
it has been shown that S1P signaling for M2 polarization occurs mainly via S1P1 and S1P2, which
results in the activation of ERK and consequent IL-4 secretion [259]. Once secreted, IL-4 binds to
IL-4Rα and IL-2Rγ receptors, induces SOCS1 and suppresses SOCS3 via stat-6 phosphorylation, and
leads to M2 macrophage polarization [259]. It emerged that, besides promoting chemotaxis and
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pro-inflammatory actions, S1P can silence immune response in macrophages, and this effect plays an
important role in cancer immune evasion [11,252,260]. Indeed, different studies demonstrated that
S1P polarizes macrophages to the M2 phenotype, and increased expression of heme oxygenase-1 was
found to play a significant role in this process [259,261–264].
Notably, S1P recently emerged as key effector molecule also within the GBM microenvironments,
important to M2-type polarization and function of TAMs. In particular, a very recent report
demonstrated that, after human macrophage activation, the rapid decrease of SphK2 expression
and activity is required for inflammatory cytokine production [265]. However, this downregulation of
SphK2 is transient, and this enzyme is upregulated later on, to act as an anti-inflammatory mediator in
human macrophages, with an inhibitory effect on inflammatory cytokine production [265]. Of interest,
SphK2 acts as anti-inflammatory protein in human macrophages by suppressing LPS-mediated NF-κB
activation and mitochondrial ROS formation, independently of its enzymatic activity [265]. Notably,
in GBM patients the expression of SphK2 correlates with TAM infiltration as well as with the Ki-67
proliferative index of the tumors [266]. From these pieces of evidence, it is tempting to speculate that
S1P in the GBM microenvironment initially recruits microglia/macrophages and then upregulates
SphK2 in these cells. This results in the changing of these monocytes from the pro-inflammatory
state to the anti-inflammatory one, favoring GBM proliferation and protecting the tumor from an
immune intervention.
An interesting study by Luo et al. [267] recently reported that dying cells effectively secrete S1P,
which acts as a ‘find-me signal’ for macrophage recruitment. The action of S1P finally resulted in
enhanced dead cell phagocytosis and immune tolerance, and occurred through activating erythropoietin
signaling in macrophages [267]. Whether this mechanism operates in cancer and in perinecrotic regions
of GBM, and contributes to its immune evasion, remains unknown.
The GBM microenvironment includes a further type of monocytic immune cell that participates to
immunosuppression, represented by myeloid-derived suppressor cells (MDSCs). These cells account
for a major subpopulation of monocytes in the blood of GBM patients, and are abundant in the GBM
microenvironments [268,269]. It was demonstrated that S1P can induce an increase in MDSC activity
in different solid cancers [270], and thus reduce the immune response. Indeed, the S1P activation of the
ERK1/2 MAPK pathway coupled to S1P3 induced an increased expression of granulocyte-macrophage
colony-stimulating factor (GM-CSF), resulting in an enrichment of MDSCs in the tumor niche, and
autocrine stimulation of immunosuppressive functions of these cells [270]. These results show that
S1P3 activation by S1P can stimulate MDSC immunosuppressive activity in the tumor niche. However,
currently, there are no studies describing the role of S1P in MDSCs of GBM.
Among immune dysfunctions of cancer patients involved in tumor immune evasion, there is
also that of T cells, T-cell lymphopenia being particularly severe in patients with GBM [271]. S1P is
increasingly recognized for its role in mediating naïve T-cell egress from lymphoid organs, a process
that is dependent on both the high S1P chemotactic gradient between lymphoid organs and blood, and
on S1P binding to its S1P1 receptor on the T-cell surface [272,273]. Both processes are altered in GBM
patients. Indeed, it was shown that the circulating level of S1P in platelet-rich plasma is significantly
reduced in GBM patients [251], reducing the chemotactic gradient that directs T-cell egress into the
circulation [32]. Interestingly, a recent study uncovered that T-cell lymphopenia in GBM patients is
associated with T-cell trapping into the bone marrow, and to the GBM-induced internalization of the
S1P1 receptor from the T-cell surface, which impairs T-cell egress from the bone marrow [274].
7.5. S1P in the Cancer Microenvironment Promotes Intense Angiogenesis
GBM exhibits extremely high vascularity, and it is among the most angiogenic tumor in humans, with
sustained endothelial activation significantly contributing to its microenvironment and progression [77].
Notably, angiogenesis represents a key process in GBM, associated with uncontrolled cell growth and
spread as well as therapy resistance, and, not least, high death rate of patients [39,275]. In addition,
the perivascular niche represents a reservoir for GSCs, which promotes tumor progression and drives
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aggressive behavior [276–278]. The major trigger of angiogenesis in GBM is hypoxia, which promotes
adaptation through HIFs, a transcription factor involved in the regulation of multiple genes [279].
Among HIF-induced angiogenic factors, VEGF plays a major role in GBM, as it boosts proliferation,
permeability, migration, and survival in ECs, and formation of immature, highly permeable blood
vessels [280,281]. Indeed, VEGF is thought to be the major angiogenic mediator in GBM [282], and
its overexpression in GBM is significantly associated with poor patient survival [283]. In hypoxic
GBM cells, SphK1 was shown to upregulate HIF-1α by stabilizing it through the Akt pathway, and
by reducing its proteasomal degradation [284]. Additionally, HIF-2α upregulates SphK1 in GBM
cells to promote neovascularization [112], and GSCs play a pivotal role in inducing angiogenesis via
HIF-1/VEGF [285].
Different studies underscore the role of S1P in ECs. It was reported that S1P is capable of acting
as a potent angiogenic factor with potency similar to VEGF, regulating both early and later stages
of angiogenesis [286], and to promote neovascularization of tumors [98]. S1P promotes endothelial
migration and proliferation, stimulates EC entubulation, and stabilizes newly formed vessels [287,288].
In ECs, S1P upregulates both mRNA and protein levels of the C2H2-zinc finger gene ZNF580, via p38
MAPK pathway [289], and S1P1 is involved in the S1P actions for migration, vascular maturation,
and effective induction of angiogenesis [290,291]. In the context of GBM, S1P was shown to initiate
microvascular EC sprouting, and SphK1 plays an essential role in regulating paracrine angiogenesis
by inducing an increase in both number and length of sprouts [50,96]. This effect was not affected by
VEGF, suggesting that S1P signaling is required even when potent angiogenic factors such as VEGF are
present. As different pro-angiogenic growth factors and cytokines, S1P and VEGF collaborate in GBM
angiogenesis, often mutually reinforcing their action [9,112,289,292]. We recently reported that S1P
acts as a potent stimulator of both migration and angiogenesis in ECs derived from different GBM
patients too, and S1P1/S1P3 receptors are involved in these effects [96].
7.6. S1P in the Cancer Microenvironment Promotes Deregulated Energy Metabolism
Among cancer hallmarks, reprogramming energy metabolism has emerged as critical, in order to
adapt to the increased nutritional requirements during the growth, division, and survival of different
cancer cells, including GBM ones [166]. Multiple studies strongly support that cancers undergo
metabolic adaptation and reprogramming, with factors intrinsic to cancer cells such as oncogenic
mutations, and cell-extrinsic microenvironmental factors substantially contributing to the metabolic
phenotype of cancer cells [293]. GBM cells demonstrate a striking ability to rewire their metabolism, the
TME contributing immensely to their metabolic reprogramming [294,295]. A key event is the increased
glycolysis under aerobic conditions (the Warburg effect), which promotes cancer cell proliferation and
survival. As in other malignant tumors, GBM cells exhibit high levels of non-oxidative metabolism
of glucose even in the presence of oxygen [296], and the upregulation of glycolysis appears to be a
universal feature in both GBM and GSCs [297]. The hypoxic microenvironment within the tumor
is a major driver of the metabolic shift toward glycolysis [298], which is crucial in providing not
only ATP but also different intermediates for anabolic metabolism, as well as adaptation to hypoxic
conditions [299–302].
It is only in the last years that S1P has emerged as a mediator of the deregulated metabolism
in cancer cells. In different solid cancers, downregulation/inhibition of SphK1 inhibits the Warburg
effect [303,304], suggesting that SphK1 overexpression in GBM contributes to efficient glycolysis.
Interestingly, a S1P3-dependent regulatory network was recently identified as a modulator of the
Warburg effect during osteosarcoma growth [305]. Moreover, S1P3-signaling activation by S1P inhibits
the phosphorylation of Yes-associated protein (YAP), promoting YAP nuclear translocation, formation
of the YAP-c-MYC complex, and finally enhancing the transcription of glycolytic enzymes [305].
The metabolic reprogramming of GBM cells is the result of a complex network of mechanisms
that, through the activation of oncogenes, induces an increased expression of cell transporters and
glycolytic enzymes. Among these oncogenes, HIFα activation by hypoxia is crucial to promote
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anaerobic glycolysis, to reduce mitochondrial respiration, and to enhance the expression of VEGF
in GBM [306]. Intriguingly, in hypoxic GBM cells, SphK1 upregulates HIF-1α [284] and stimulates
the production and secretion of VEGF [181], suggesting that S1P acts as a signal involved in GBM
metabolic rewiring.
Among intermediates of glucose metabolism in GBM cells, cytosolic glucose-6-phosphate (G6P)
functions as negative regulator of the intracellular signaling and invasive phenotype, and its transfer
into the ER through the microsomal G6P translocase is highly efficient in GBM cells [210]. Interestingly,
S1P-induced ERK phosphorylation and migration of GBM cells was inhibited after treatment with
chlorogenic acid, a G6P translocase inhibitor [210], suggesting that cytosolic G6P acts as an inhibitor of
S1P signaling. On this basis, it can be speculated that the microsomal segregation of G6P, as well as the
low G6P levels in GBM [295], prompts S1P signaling.
Despite these novel pieces of evidence suggesting a role of S1P in tumor metabolic aberrations,
further studies are needed to explore this less-studied aspect of S1P signaling. In this context, it is worth
mentioning that, among different metabolic deregulations, aberrant lipid metabolism has emerged as
crucial, not only as an energy source and in providing substrates for membrane synthesis, but also for
its role in cellular signaling in both GBM cells and GSCs [307,308]. Concerning lipid signaling, different
studies demonstrated that lysophosphatidic acid (LPA), a major membrane-derived lipid-signaling
molecule beside S1P, acts as a key player in GBM [309,310]. LPA is generated extracellularly from
lysophosphatidylcholine through the action of autotaxin (ATX), and, similar to S1P, exerts potent
cancer-promoting effects through G protein-coupled receptors. Interestingly, ATX can also hydrolyze
sphingophosphorylcholine to produce S1P [311], and S1P has been shown to inhibit ATX [312] through
regulation of transcription and secretion [313]. Despite these intriguing interconnections between LPA
and S1P metabolism, and a cross-talk between these two lysophospholipids in gastric cancer [314], up
until now the interaction between S1P and LPA metabolism/signaling in GBM remains unexplored.
8. Conclusions
S1P is emerging as a key signal in the reciprocal cross-talk between cancer cells and recruited
normal cells in the TME, as well as in their interplay with the TME, complex processes crucial for tumor
growth and progression. GBM, one of the most lethal of all human malignancies, is characterized by
a unique TME, enriched in S1P, which enables intensive growth and efficient invasion mechanisms,
fosters stemness, impairs immune surveillance, promotes angiogenesis, and mediates death resistance.
More specifically, cancer cells and GSCs cooperate with resident host cells, including TAMs and ECs, as
well as other brain cells, to enrich the TME with S1P. On its turn, S1P acts as a potent tumor-promoter,
and supports tumor progression by contributing to all its malignant hallmarks.
The findings reported above, and particularly the impact of S1P in promoting cancer hallmarks
(Figure 3), have clear implications for cancer treatment. Indeed, S1P targeting has emerged as a
promising therapy for cancer/GBM patients [315]. Significant efforts have been made (and are on track)
for the synthesis, identification, and therapeutic evaluation of S1P-targeting drugs in different cancers,
including GBM. Many recent investigations, both in cultured cells and in experimental animals, are
promising. Among them, promising studies have been carried out using drugs targeting enzymes
of S1P metabolism, such as SphKs [65,316,317] and acid ceramidase [318], S1P transporters [319],
and S1P receptors and signaling [232,320,321]. Of particular interest is the S1P receptor antagonist
FTY720 (Gilenya/Fingolimod), which demonstrated efficacy in multiple sclerosis and has been used in
numerous animal experiments and clinical trials for different diseases and cancers, including GBM
(Clinicaltrials.gov, NCT02490930, sponsored by Sidney Kimmel Comprehensive Cancer).
Although the targeting of S1P appears an extremely attractive strategy in permitting the inhibition of
cancer hallmarks, key issues deserve attention. First, a detailed, comprehensive understanding of S1P
regulation (production, extracellular export, and degradation) and of S1P receptor expression/interaction
is required for a full understanding of the role of S1P in the TME. Second, crucial to the use of S1P signaling
as a target in cancer is elucidation of how the diversity of TMEs contributes to their S1P enrichment and
Cells 2020, 9, 337 21 of 37
understanding of the S1P-signaling circuits that operate across different cells in the TME. The key to
resolving this is an expansion of our mechanistic understanding about the actual role of S1P on various
cells in the TME, and which of the diverse effects of S1P are relevant to the maintenance/progression of
cancer. Third, despite the requirement for S1P signaling emerging as a crucial mechanism that conspires in
tumorigenesis, this signaling appears a basic need for most types of cells to live. Thus, targeting S1P should
be well balanced between the agreeable outcome of eradicating malignant cells and the menace afforded
to healthy normal cells/tissues. Fourth and last, but not least, the heterogeneity of individual cancers,
particularly of GBM, might require patient-specific personalized therapies based on responsiveness to
treatments. In this regard, the possibility to develop a patient-specific S1P panel might be of help in
selecting S1P-based target therapies. Going further with this knowledge should help close the gaps in our
understanding of the role of S1P in GBM/cancer progression, and pave the way for the identification of
target key modules in S1P signaling with maximum potency and selectivity for cancer. Although the
challenges are still substantial, past and recent advancements support the idea that further breakthroughs
will occur in the near future, with impact.
Author Contributions: All authors contributed extensively to the work presented in this review. All authors have
read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Maceyka, M.; Harikumar, K.B.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate signaling and its role in
disease. Trends Cell. Biol. 2012, 22, 50–60. [CrossRef] [PubMed]
2. Kostenis, E. Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and
(lyso)-phosphatidic acid: New receptors for “old” ligands. J. Cell. Biochem. 2004, 92, 923–936. [CrossRef]
[PubMed]
3. Hait, N.C.; Allegood, J.; Maceyka, M.; Strub, G.M.; Harikumar, K.B.; Singh, S.K.; Luo, C.; Marmorstein, R.;
Kordula, T.; Milstien, S.; et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.
Science 2009, 325, 1254–1257. [CrossRef] [PubMed]
4. Strub, G.M.; Maceyka, M.; Hait, N.C.; Milstien, S.; Spiegel, S. Extracellular and intracellular actions of
sphingosine-1-phosphate. Adv. Exp. Med. Biol. 2010, 688, 141–155. [PubMed]
5. Nagahashi, M.; Abe, M.; Sakimura, K.; Takabe, K.; Wakai, T. The role of sphingosine-1-phosphate in
inflammation and cancer progression. Cancer Sci. 2018, 109, 3671–3678. [CrossRef]
6. Ogretmen, B. Sphingolipid metabolism in cancer signalling and therapy. Nat. Rev. Cancer. 2018, 18, 33–50.
[CrossRef]
7. Pyne, N.J.; El Buri, A.; Adams, D.R.; Pyne, S. Sphingosine 1-phosphate and cancer. Adv. Biol. Regul. 2018, 8,
97–106. [CrossRef]
8. Wang, P.; Yuan, Y.; Lin, W.; Zhong, H.; Xu, K.; Qi, X. Roles of sphingosine-1-phosphate signaling in cancer.
Cancer Cell. Int. 2019, 19, 295. [CrossRef]
9. Abdel Hadi, L.; Di Vito, C.; Marfia, G.; Navone, S.N.; Campanella, R.; Riboni, L. The role and function
of sphingolipids in glioblastoma multiforme. In Bioactive Sphingolipids in Cancer Biology and Therapy;
Hannun, Y.A., Luberto, C., Mao, C., Obeid, L.M., Eds.; Springer International Publishing: Cham, Switzerland,
2015; pp. 259–291.
10. Mahajan-Thakur, S.; Bien-Möller, S.; Marx, S.; Schroeder, H.; Rauch, B.H. Sphingosine 1-phosphate (S1P)
signaling in glioblastoma multiforme - A systematic review. Int. J. Mol. Sci. 2017, 18, 2448. [CrossRef]
11. Korbecki, J.; Gutowska, I.; Kojder, I.; Jez˙ewski, D.; Goschorska, M.; Łukomska, A.; Chlubek, D.;
Baranowska-Bosiacka, I. New extracellular factors in glioblastoma multiforme development: Neurotensin,
growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection. Oncotarget 2018, 9,
7219–7270. [CrossRef]
12. Haddadi, N.; Lin, Y.; Simpson, A.M.; Nassif, N.T.; McGowan, E.M. “Dicing and splicing” sphingosine kinase
and relevance to cancer. Int. J. Mol. Sci. 2017, 18, 1891. [CrossRef]
Cells 2020, 9, 337 22 of 37
13. Merrill, A.H., Jr. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.
Chem. Rev. 2011, 111, 6387–6422. [CrossRef] [PubMed]
14. Hatoum, D.; Haddadi, N.; Lin, Y.; Nassif, N.T.; McGowan, E.M. Mammalian sphingosine kinase (SphK)
isoenzymes and isoform expression: Challenges for SphK as an oncotarget. Oncotarget 2017, 8, 36898–36929.
[CrossRef] [PubMed]
15. Pulkoski-Gross, M.J.; Obeid, L.M. Molecular mechanisms of regulation of sphingosine kinase 1.
Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2018, 1863, 1413–1422. [CrossRef]
16. Song, D.D.; Zhou, J.H.; Sheng, R. Regulation and function of sphingosine kinase 2 in diseases. Histol. Histopathol.
2018, 33, 433–445.
17. Pitson, S.M. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci. 2011, 36,
97–107. [CrossRef]
18. Siow, D.; Wattenberg, B. The compartmentalization and translocation of the sphingosine kinases: Mechanisms
and functions in cell signaling and sphingolipid metabolism. Crit. Rev. Biochem. Mol. Biol. 2011, 46, 365–375.
[CrossRef]
19. Neubauer, H.A.; Pitson, S.M. Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J. 2013, 280,
5317–5336. [CrossRef]
20. Newton, J.; Lima, S.; Maceyka, M.; Spiegel, S. Revisiting the sphingolipid rheostat: Evolving concepts in
cancer therapy. Exp. Cell Res. 2015, 333, 195–200. [CrossRef]
21. Spiegel, S.; Milstien, S. Functions of the multifaceted family of sphingosine kinases and some close relatives.
J. Biol. Chem. 2007, 282, 2125–2129. [CrossRef]
22. Proia, R.L.; Hla, T. Emerging biology of sphingosine-1-phosphate: Its role in pathogenesis and therapy.
J. Clin. Investig. 2015, 125, 1379–1387. [CrossRef] [PubMed]
23. Ancellin, N.; Colmont, C.; Su, J.; Li, Q.; Mittereder, N.; Chae, S.S.; Stefansson, S.; Liau, G.; Hla, T. Extracellular
export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic
vascular maturation. J. Biol. Chem. 2002, 277, 6667–6675. [CrossRef] [PubMed]
24. Venkataraman, K.; Thangada, S.; Michaud, J.; Oo, M.L.; Ai, Y.; Lee, Y.M.; Wu, M.; Parikh, N.S.; Khan, F.;
Proia, R.L.; et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient.
Biochem. J. 2006, 397, 461–471. [CrossRef] [PubMed]
25. Weigert, A.; Cremer, S.; Schmidt, M.V.; von Knethen, A.; Angioni, C.; Geisslinger, G.; Brune, B. Cleavage
of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood 2010, 115, 3531–3540.
[CrossRef] [PubMed]
26. Heffernan-Stroud, L.A.; Obeid, L.M. Sphingosine kinase 1 in cancer. Adv. Cancer Res. 2013, 117, 201–235.
[PubMed]
27. Wang, Q.; Li, J.; Li, G.; Li, Y.; Xu, C.; Li, M.; Xu, G.; Fu, S. Prognostic significance of sphingosine kinase 2
expression in non-small cell lung cancer. Tumour Biol. 2014, 35, 363e368.
28. Ikeda, M.; Kihara, A.; Igarashi, Y. Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulum-resident,
integral membrane protein with the pyridoxal 5′-phosphate binding domain exposed to the cytosol.
Biochem. Biophys. Res. Commun. 2004, 325, 338–343. [CrossRef]
29. Le Stunff, H.; Peterson, C.; Liu, H.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate and lipid phosphohydrolases.
Biochim. Biophys. Acta 2002, 1582, 8–17. [CrossRef]
30. Tang, X.; Benesch, M.G.; Brindley, D.N. Lipid phosphate phosphatases and their roles in mammalian
physiology and pathology. J. Lipid Res. 2015, 56, 2048–2060. [CrossRef]
31. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P.G.; Coso, O.A.; Gutkind, S.; Spiegel, S. Suppression
of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996, 381, 800–803.
[CrossRef]
32. Olivera, A.; Allende, M.L.; Proia, R.L. Shaping the landscape: Metabolic regulation of S1P gradients.
Biochim. Biophys. Acta 2013, 1831, 193–202. [CrossRef]
33. Nishi, T.; Kobayashi, N.; Hisano, Y.; Kawahara, A.; Yamaguchi, A. Molecular and physiological functions of
sphingosine 1-phosphate transporters. Biochim. Biophys. Acta 2014, 1841, 759–765. [CrossRef]
34. Kobayashi, N.; Kawasaki-Nishi, S.; Otsuka, M.; Hisano, Y.; Yamaguchi, A.; Nishi, T. MFSD2B is a sphingosine
1-phosphate transporter in erythroid cells. Sci. Rep. 2018, 8, 4969. [CrossRef]
35. Zhu, X.; Ren, K.; Zeng, Y.-Z.; Zheng, Z.; Yi, G.H. Biological function of SPNS2: From zebrafish to human.
Mol. Immunol. 2018, 103, 55–62. [CrossRef] [PubMed]
Cells 2020, 9, 337 23 of 37
36. Vu, T.M.; Ishizu, A.N.; Foo, J.C.; Toh, X.R.; Zhang, F.; Whee, D.M.; Torta, F.; Cazenave-Gassiot, A.;
Matsumura, T.; Kim, S.; et al. Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and
platelets. Nature 2017, 550, 524–528. [CrossRef] [PubMed]
37. Ksia˛z˙ek, M.; Chacin´ska, M.; Chabowski, A.; Baranowski, M. Sources, metabolism, and regulation of
circulating sphingosine-1-phosphate. Lipid Res. 2015, 56, 1271–1281. [CrossRef]
38. Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.;
Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization classification of tumors of the
central nervous system: A summary. Acta Neuropathol. 2016, 31, 803–820. [CrossRef] [PubMed]
39. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492–507. [CrossRef] [PubMed]
40. Rees, J. Tumors of the brain. In Neurology and Clinical Neuroscience; Schapira, A.H.V., Ed.; Mosby Elsevier:
Philadelphia, PA, USA, 2007; pp. 1324–1339.
41. Johnson, D.R.; O’Neill, B.P. Glioblastoma survival in the United States before and during the temozolomide
era. J. Neurooncol. 2012, 107, 359–364. [CrossRef] [PubMed]
42. Gallego, O. Nonsurgical treatment of recurrent glioblastoma. Curr. Oncol. 2015, 22, e273–e281. [CrossRef]
[PubMed]
43. Ostrom, Q.T.; Gittleman, H.; Xu, J.; Kromer, C.; Wolinsky, Y.; Kruchko, C.; Barnholtz-Sloan, JS. CBTRUS
statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in
2009–2013. Neuro Oncol. 2016, 18, v1–v75. [CrossRef]
44. Henriksson, R.; Asklund, T.; Poulsen, H.S. Impact of therapy on quality of life, neurocognitive function and
their correlates in glioblastoma multiforme: A review. J. Neurooncol. 2011, 104, 639–646. [CrossRef]
45. Wilson, C.B. Glioblastoma: The past, the present, and the future. Clin. Neurosurg. 1992, 38, 32–48.
46. Glas, M.; Rath, B.H.; Simon, M.; Reinartz, R.; Schramme, A.; Trageser, D.; Eisenreich, R.; Leinhaas, A.;
Keller, M.; Schildhaus, H.-U.; et al. Residual tumor cells are unique cellular targets in glioblastoma.
Ann. Neurol. 2010, 68, 264–269. [CrossRef]
47. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61, 212e36. [CrossRef] [PubMed]
48. Serwer, L.P.; James, C.D. Challenges in drug delivery to tumors of the central nervous system: An overview of
pharmacological and surgical considerations. Adv. Drug Deliv. Rev. 2012, 64, 590–597. [CrossRef] [PubMed]
49. Riboni, L.; Campanella, R.; Bassi, R.; Villani, R.; Gaini, S.M.; Martinelli-Boneschi, F.; Viani, P.; Tettamanti, G.
Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 2002, 39,
105–113. [CrossRef]
50. Abuhusain, H.J.; Matin, A.; Qiao, Q.; Shen, H.; Kain, N.; Day, B.W.; Stringer, B.W.; Daniels, B.; Laaksonen, M.A.;
Teo, C.; et al. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls
glioblastoma angiogenesis. J. Biol. Chem. 2013, 288, 37355–37364. [CrossRef]
51. Hannun, Y.A.; Obeid, L.M. Many ceramides. J. Biol. Chem. 2011, 286, 27855–27862. [CrossRef]
52. Senkal, C.E.; Ponnusamy, S.; Rossi, M.J.; Bialewski, J.; Sinha, D.; Jiang, J.C.; Jazwinski, S.M.; Hannun, Y.A.;
Ogretmen, B. Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell
death in human head and neck squamous cell carcinomas. Mol. Cancer Ther. 2007, 6, 712–722. [CrossRef]
53. Sullards, M.C.; Wang, E.; Peng, Q.; Merrill, A.H., Jr. Metabolomic profiling of sphingolipids in human glioma
cell lines by liquid chromatography tandem mass spectrometry. Cell. Mol. Biol. 2003, 49, 789–797. [PubMed]
54. Van Brocklyn, J.R.; Jackson, C.A.; Pearl, D.K.; Kotur, M.S.; Snyder, P.J.; Prior, T.W. Sphingosine kinase-1
expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine
kinase isoforms in growth of glioblastoma cell lines. J. Neuropathol. Exp. Neurol. 2005, 64, 695–705. [CrossRef]
[PubMed]
55. Li, J.; Guan, H.Y.; Gong, L.Y.; Song, L.-B.; Zhang, N.; Wu, J.; Yuan, J.; Zheng, Y.-J.; Huang, Z.-S.; Li, M. Clinical
significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient
survival. Clin. Cancer Res. 2008, 14, 6996–7003. [CrossRef]
56. Quint, K.; Stiel, N.; Neureiter, D.; Schlicker, H.U.; Nimsky, C.; Ocker, M.; Strik, H.; Kolodziej, M.A. The role of
sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent
glioblastomas. Tum. Biol. 2014, 35, 8979–8989. [CrossRef] [PubMed]
57. Bien-Möller, S.; Lange, S.; Holm, T.; Bohm, A.; Paland, H.; Kupper, J.; Herzog, S.; Weitmann, K.; Havemann, C.;
Vogelgesang, S.; et al. Expression of S1P metabolizing enzymes and receptors correlate with survival time and
regulate cell migration in glioblastoma multiforme. Oncotarget 2016, 7, 13031–13046. [CrossRef] [PubMed]
Cells 2020, 9, 337 24 of 37
58. Yoshida, Y.; Nakada, M.; Harada, T.; Tanaka, S.; Furuta, T.; Hayashi, Y.; Kita, D.; Uchiyama, N.; Hayashi, Y.;
Hamada, J. The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling
index and predicts survival of glioblastoma patients. J. Neurooncol. 2010, 98, 41–47. [CrossRef]
59. Postepska-Igielska, A.; Giwojna, A.; Gasri-Plotnitsky, L.; Schmitt, N.; Dold, A.; Ginsberg, D.; Grummt, I.
LncRNA Khps1 regulates expression of the proto-oncogene SPHK1 via triplex-mediated changes in chromatin
structure. Mol. Cell. 2015, 60, 626–636. [CrossRef]
60. Kiang, K.M.; Zhang, X.-Q.; Leung, G.K. Long Non-Coding RNAs: The key players in glioma pathogenesis.
Cancers 2015, 7, 1406–1424. [CrossRef]
61. Donaires, F.S.; Godoy, P.R.; Leandro, G.S.; Puthier, D.; Sakamoto-Hojo, E.T. E2F transcription factors associated
with up-regulated genes in glioblastoma. Cancer Biomark. 2017, 18, 199–208. [CrossRef]
62. Yagoub, D.; Wilkins, M.R.; Lay, A.J.; Kaczorowski, D.C.; Hatoum, D.; Bajan, S.; Hutvagner, G.; Lai, J.H.;
Wu, W.; Martiniello-Wilks, R.; et al. Sphingosine kinase 1 isoform-specific interactions in breast cancer.
Mol. Endocrinol. 2014, 28, 1899–1915. [CrossRef]
63. Lim, K.G.; Tonelli, F.; Berdyshev, E.; Gorshkovab, I.; Leclercq, T.; Pitson, S.M.; Bittman, R.; Pyne, S.; Pyne, N.J.
Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: Functional
differences between sphingosine kinase 1a and 1b. Int. J. Biochem. Cell. Biol. 2012, 44, 1457–1464. [CrossRef]
[PubMed]
64. Okada, T.; Ding, G.; Sonoda, H.; Kajimoto, T.; Haga, Y.; Khosrowbeygi, A.; Gao, N.; Miwa, S.; Jahangeer, S.;
Nakamura, J. Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent
regulation of cell proliferation and apoptosis. J. Biol. Chem. 2005, 280, 36318–36325. [CrossRef] [PubMed]
65. Sordillo, L.A.; Sordillo, P.P.; Helson, L. Sphingosine kinase inhibitors as maintenance therapy of glioblastoma
after ceramide-induced response. Anticancer Res. 2016, 36, 2085–2095. [PubMed]
66. Jensen, S.A.; Calvert, A.E.; Volpert, G.; Kouri, F.M.; Hurley, L.A.; Luciano, J.P.; Wu, Y.; Chalastanis, A.;
Futerman, A.H.; Stegh, A.H. Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc. Natl. Acad.
Sci. USA 2014, 111, 5682–5687. [CrossRef] [PubMed]
67. Tettamanti, G.; Bassi, R.; Viani, P.; Riboni, L. Salvage pathways in glycosphingolipid metabolism. Biochimie
2003, 85, 423–437. [CrossRef]
68. Dilillo, M.; Ait-Belkacem, R.; Esteve, C.; Pellegrini, D.; Nicolardi, S.; Costa, M.; Vannini, E.; de Graaf, E.L.;
Caleo, M.; McDonnell, L.A. Ultra-High Mass Resolution MALDI Imaging Mass Spectrometry of Proteins
and Metabolites in a Mouse Model of Glioblastoma. Sci. Rep. 2017, 7, 603. [CrossRef]
69. Doan, N.B.; Nguyen, H.S.; Alhajala, H.S.; Jaber, B.; Al-Gizawiy, M.M.; Ahn, E.E.; Mueller, W.M.;
Chitambar, C.R.; Mirza, S.P.; Schmainda, K.M. Identification of radiation responsive genes and transcriptome
profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model. Oncotarget 2018,
9, 23532–23542. [CrossRef]
70. Steck, P.A.; Ligon, A.H.; Cheong, P.; Yung, W.K.; Pershouse, MA. Two tumor suppressive loci on chromosome
10 involved in human glioblastomas. Genes Chromosomes Cancer 1995, 12, 255–261. [CrossRef]
71. Ogawa, C.; Kihara, A.; Gokoh, M.; Igarashi, Y. Identification and characterization of a novel human
sphingosine-1-phosphate phosphohydrolase, hSPP2. J. Biol. Chem. 2003, 278, 1268–1272. [CrossRef]
72. Mora, R.; Dokic, I.; Kees, T.; Hüber, C.M.; Keitel, D.; Geibig, R.; Brügge, B.; Zentgraf, H.; Brady, N.R.;
Régnier-Vigouroux, A. Sphingolipid rheostat alterations related to transformation can be exploited for
specific induction of lysosomal cell death in murine and human glioma. Glia 2010, 58, 1364–1383. [CrossRef]
73. Qin, J.; Berdyshev, E.; Goya, J.; Natarajan, V.; Dawson, G. Neurons and oligodendrocytes recycle sphingosine
1-phosphate to ceramide: Significance for apoptosis and multiple sclerosis. J. Biol. Chem. 2010, 285,
14134–14143. [CrossRef] [PubMed]
74. Brizuela, L.; Ader, I.; Mazerolles, C.; Bocquet, M.; Malavaud, B.; Cuvillier, O. First evidence of sphingosine
1-phosphate lyase protein expression and activity downregulation in human neoplasm: Implication for
resistance to therapeutics in prostate cancer. Mol. Cancer Ther. 2012, 11, 1841–1851. [CrossRef] [PubMed]
75. Kurek, K.; Łukaszuk, B.; S´widnicka-Siergiejko, A.; Rogalski, P.; Wróblewski , E.; Chabowski, A.; Da˛browski, A.;
Z˙endzian-Piotrowska, M. Sphingolipid metabolism in colorectal adenomas varies depending on histological
architecture of polyps and grade of nuclear dysplasia. Lipids 2015, 50, 349–358. [CrossRef] [PubMed]
76. Shimizu, Y.; Furuya, H.; Tamashiro, P.M.; Iino, K.; Chan, O.T.M.; Goodison, S.; Pagano, I.; Hokutan, K.;
Peres, R.; Loo, L.W.M.; et al. Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor
development in an HER2 transgenic model. Carcinogenesis 2018, 39, 47–55. [CrossRef] [PubMed]
Cells 2020, 9, 337 25 of 37
77. Quail, D.F.; Joyce, J.A. The microenvironmental landscape of brain tumors. Cancer Cell 2017, 31, 326–341.
[CrossRef] [PubMed]
78. Fang, H.; Declerck, Y.A. Targeting the tumor microenvironment: From understanding pathways to effective
clinical trials. Cancer Res. 2013, 73, 4965–49774. [CrossRef]
79. Charles, N.A.; Holland, E.C.; Gilbertson, R.; Glass, R.; Kettenmann, H. The brain tumor microenvironment.
Glia 2011, 59, 1169–1180. [CrossRef]
80. Swartling, F.J.; Hede, S.-M.; Weiss, W.A. What underlies the diversity of brain tumors? Cancer Metastasis Rev.
2013, 32, 5–24. [CrossRef]
81. Broekman, M.L.; Maas, S.L.N.; Abels, E.R.; Mempel, T.R.; Krichevsky, A.M.; Breakefield, X.O. Multidimensional
communication in the microenvirons of glioblastoma. Nat. Rev. Neurol. 2018, 14, 482–495. [CrossRef]
82. Persano, L.; Rampazzo, E.; Basso, G.; Viola, G. Glioblastoma cancer stem cells: Role of the microenvironment
and therapeutic targeting. Biochem. Pharmacol. 2013, 85, 612–622. [CrossRef]
83. Brat, D.J.; Van Meir, E.G. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia,
necrosis, and accelerated growth in glioblastoma. Lab. Investig. 2004, 84, 397–405. [CrossRef]
84. Peitzsch, C.; Perrin, R.; Hill, R.P.; Dubrovska, A.; Kurth, I. Hypoxia as a biomarker for radioresistant cancer
stem cells. Int. J. Radiat. Biol. 2014, 90, 636–652. [CrossRef] [PubMed]
85. Peng, G.; Liu, Y. Hypoxia-Inducible Factors in Cancer Stem Cells and Inflammation. Trends Pharmacol. Sci.
2015, 36, 374–383. [CrossRef] [PubMed]
86. Kitamura, T.; Qian, B.-Z.; Pollard, J.W. Immune cell promotion of metastasis. Nat. Rev. Immunol. 2015, 15,
73–86. [CrossRef]
87. Uribe, D.; Torres, Á.; Rocha, J.D.; Niechi, I.; Oyarzún, C.; Sobrevia, L.; San Martín, R.; Quezada, C. Multidrug
resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling.
Mol. Asp. Med. 2017, 55, 140–151. [CrossRef] [PubMed]
88. Hambardzumyan, D.; Bergers, G. Glioblastoma: Defining tumor niches. Trends Cancer 2015, 1, 252–265.
[CrossRef]
89. Filatova, A.; Acker, T.; Garvalov, B.K. The cancer stem cell niche(s): The crosstalk between glioma stem cells
and their microenvironment. Biochim. Biophys. Acta 2013, 1830, 2496–2508. [CrossRef]
90. Infanger, D.W.; Cho, Y.; Lopez, B.S.; Mohanan, S.; Liu, S.C.; Gursel, D.; Boockvar, J.A.; Fischbach, C.
Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Cancer Res.
2013, 73, 7079–7089. [CrossRef]
91. Riboni, L.; Giussani, P.; Viani, P. Sphingolipid transport. Adv. Exp. Med. Biol. 2010, 688, 24–45.
92. Takabe, K.; Spiegel, S. Export of sphingosine-1-phosphate and cancer progression. J. Lipid Res. 2014, 55,
1839–1846. [CrossRef]
93. Edsall, L.C.; Cuvillier, O.; Twitty, S.; Spiegel, S.; Milstien, S. Sphingosine kinase expression regulates apoptosis
and caspase activation in PC12 cells. J. Neurochem. 2001, 76, 1573–1584. [CrossRef] [PubMed]
94. Anelli, V.; Gault, C.R.; Snider, A.J.; Obeid, L.M. Role of sphingosine kinase-1 in paracrine/transcellular
angiogenesis and lymphangiogenesis in vitro. FASEB J. 2010, 24, 2727–2738. [CrossRef]
95. Riccitelli, E.; Giussani, P.; Di Vito, C.; Condomitti, G.; Tringali, C.; Caroli, M.; Galli, R.; Viani, P.; Riboni, L.
Extracellular sphingosine-1-phosphate: A novel actor in human glioblastoma stem cell survival. PLoS ONE
2013, 8, e68229. [CrossRef] [PubMed]
96. Abdel Hadi, L.; Anelli, V.; Guarnaccia, L.; Navone, S.; Beretta, M.; Moccia, F.; Tringali, C.; Urechie, V.;
Campanella, R.; Marfia, G.; et al. A bidirectional crosstalk between glioblastoma and brain endothelial
cells potentiates the angiogenic and proliferative signaling of sphingosine-1-phosphate in the glioblastoma
microenvironment. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2018, 1863, 1179–1192. [CrossRef] [PubMed]
97. Bassi, R.; Anelli, V.; Giussani, P.; Tettamanti, G.; Viani, P.; Riboni, L. Sphingosine-1-phosphate is released by
cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled
receptors. Glia 2006, 53, 621–630. [CrossRef] [PubMed]
98. LaMontagne, K.; Littlewood-Evans, A.; Schnell, C.; O’Reilly, T.; Wyder, L.; Sanchez, T.; Probst, B.; Butler, J.;
Wood, A.; Liau, G.; et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis
and tumor vascularization. Cancer Res. 2006, 66, 221–231. [CrossRef] [PubMed]
99. Paugh, B.S.; Paugh, S.W.; Bryan, L.; Kapitonov, D.; Wilczynska, K.M.; Gopalan, S.M.; Rokita, H.; Milstien, S.;
Spiegel, S.; Kordula, T. EGF regulates plasminogen activator inhibitor-1 by a pathway involving c-Src, PKCδ,
and sphingosine kinase 1 in glioblastoma cells. FASEB J. 2008, 22, 455–465. [CrossRef]
Cells 2020, 9, 337 26 of 37
100. Riboni, L.; Viani, P.; Bassi, R.; Stabilini, A.; Tettamanti, G. Biomodulatory role of ceramide in basic fibroblast
growth-factor induced proliferation of cerebellar astrocytes in primary culture. Glia 2000, 32, 137–145.
[CrossRef]
101. Sukocheva, O.; Wadham, C.; Holmes, A.; Albanese, N.; Verrier, E.; Feng, F.; Bernal, A.; Derian, C.K.; Ullrich, A.;
Vadas, M.A.; et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: The role
of sphingosine kinase-1. J. Cell. Biol. 2006, 173, 301–310. [CrossRef]
102. Chen, C.H.; Chen, P.Y.; Lin, Y.Y.; Feng, L.Y.; Chen, S.H.; Chen, C.Y.; Huang, Y.C.; Huang, C.Y.; Jung, S.M.;
Chen, L.Y.; et al. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma.
J. Neurosurg. 2019, 11, 1–12. [CrossRef]
103. Cattaneo, M.G.; Vanetti, C.; Samarani, M.; Aureli, M.; Bassi, R.; Sonnino, S.; Giussani, P. Cross-talk between
sphingosine-1-phosphate and EGFR signaling pathways enhances human glioblastoma cell invasiveness.
FEBS Lett. 2018, 592, 949–961. [CrossRef] [PubMed]
104. Meyer zu Heringdorf, D.; Lass, H.; Kuchar, I.; Lipinski, M.; Alemany, R.; Rumenapp, U.;
Jakobs, K.H. Stimulation of intracellular sphingosine-1-phosphate production by G-protein-coupled
sphingosine-1-phosphate receptors. Eur. J. Pharmacol. 2001, 145–154.
105. Blom, T.; Bergelin, N.; Meinander, A.; Löf, L.; Slotte, J.P.; Eriksson, J.E.; Törnquist, K. An autocrine
sphingosine-1-phosphate signaling loop enhances NF-κB-activation and survival. BMC Cell. Biol. 2010, 11,
45. [CrossRef] [PubMed]
106. Alvarez, S.E.; Milstien, S.; Spiegel, S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends
Endocrinol. Metab. 2007, 18, 300–307. [CrossRef] [PubMed]
107. Chan, H.; Pitson, S.M. Post-translational regulation of sphingosine kinases. Biochim. Biophys. Acta 2013, 1831,
147–156. [CrossRef] [PubMed]
108. Libermann, T.A.; Nusbaum, H.R.; Razon, N.; Kris, R.; Lax, I.; Soreq, H.; Whittle, N.; Waterfield, M.D.;
Ullrich, A.; Schlessinger, J. Amplification, enhanced expression and possible rearrangement of EGF receptor
gene in primary human brain tumours of glial origin. Nature 1985, 313, 144–147. [CrossRef]
109. Bryan, L.; Kordula, T.; Spiegel, S.; Milstien, S. Regulation and functions of sphingosine kinases in the brain.
Biochim. Biophys. Acta 2008, 1781, 459–466. [CrossRef]
110. Lu, T.; Tian, L.; Han, Y.; Vogelbaum, M.; Stark, G.R. Dose-dependent cross-talk between the transforming
growth factor-β and interleukin-1 signaling pathways. Proc. Natl. Acad. Sci. USA 2007, 104, 4365–4370.
[CrossRef]
111. Paugh, B.S.; Bryan, L.; Paugh, S.W.; Wilczynska, K.M.; Alvarez, S.M.; Singh, S.K.; Rokita, H.; Wright, S.;
Griswold-Prenner, I.; Milstien, S.; et al. Interleukin-1 regulates the expression of sphingosine kinase 1 in
glioblastoma cells. J. Biol. Chem. 2009, 284, 3408–3417. [CrossRef]
112. Anelli, V.; Gault, C.R.; Cheng, A.B.; Obeid, L.M. Sphingosine kinase 1 is up-regulated during hypoxia
in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J. Biol. Chem. 2008, 283, 3365–3375.
[CrossRef]
113. Zhang, H.; Li, W.; Sun, S.; Yu, S.; Zhang, M.; Zou, F. Inhibition of sphingosine kinase 1 suppresses proliferation
of glioma cells under hypoxia by attenuating activity of extracellular signal-regulated kinase. Cell Prolif.
2012, 45, 167–175. [CrossRef] [PubMed]
114. Bouquerel, P.; Gstalder, C.; Müller, D.; Laurent, J.; Brizuela, L.; Sabbadini, R.A.; Malavaud, B.; Pyronnet, S.;
Martineau, Y.; Ader, I.; et al. Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α
expression and activity in cancer. Oncogene 2016, 5, e209. [CrossRef] [PubMed]
115. Kim, S.-H.; Kim, E.-J.; Hitomi, M.; Oh, S.-Y.; Jin, X.; Jeon, H.-M.; Beck, S.; Jin, X.; Kim, J.-K.; Park, C.G.; et al.
The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.
Cell Death Differ. 2015, 22, 1517–1525. [CrossRef]
116. Matrone, G.; Meng , S.; Gu, Q.; Lv, J.; Fang, L.; Chen, K.; Cooke, J.P. Lmo2 (LIM-Domain-Only 2) modulates
Sphk1 (sphingosine kinase) and promotes endothelial cell migration. Arter. Thromb. Vasc. Biol. 2017, 37,
1860–1868. [CrossRef]
117. Rigogliuso, S.; Donati, C.; Cassarà, D.; Taverna, S.; Salamone, M.; Bruni, P.; Vittorelli, L.M. An active form of
sphingosine kinase-1 is released in the extracellular medium as component of membrane vesicles shed by
two human tumor cell lines. J. Oncol. 2010. [CrossRef]
Cells 2020, 9, 337 27 of 37
118. Nojima, H.; Freeman, C.M.; Schuster, R.M.; Japtok, L.; Kleuser, B.; Edwards, M.J.; Gulbins, E.; Lentsch, A.B.
Hepatocyte exosomes mediate liver repair and regeneration via sphingosine-1-phosphate. J. Hepatol. 2016,
64, 60–68. [CrossRef]
119. Mohamed, N.N.B.; Okada, T.; Kajimoto, T.; Nakamura, S.-I. Essential role of sphingosine kinase 2 in the
regulation of cargo contents in the exosomes from K562 cells. J. Med. Sci. 2017, 63, E123–E129.
120. Neubauer, H.A.; Tea, M.N.; Zebol, J.R.; Gliddon, B.L.; Stefanidis, C.; Moretti, P.A.B.; Pitman, M.R.;
Costabile, M.; Kular, J.; Stringer, B.W.; et al. Cytoplasmic dynein regulates the subcellular localization of
sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma. Oncogene 2019, 38, 1151–1165.
[CrossRef]
121. Bernhart, E.; Damm, S.; Wintersperger, A.; Nusshold, C.; Brunner, A.M.; Plastira, I.; Rechberger, G.; Reicher, H.;
Wadsack, C.; Zimmer, A.; et al. Interference with distinct steps of sphingolipid synthesis and signaling
attenuates proliferation of U87MG glioma cells. Biochem. Pharm. 2015, 96, 119–130. [CrossRef]
122. Eibinger, G.; Fauler, G.; Bernhart, E.; Frank, S.; Hammer, A.; Wintersperger, A.; Eder, H.; Heinemann, A.;
Mischel, P.S.; Malle, E.; et al. On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines.
Implications for chemotactic monocyte recruitment. Exp. Cell Res. 2013, 319, 1828–1838. [CrossRef]
123. Marfia, G.; Campanella, R.; Navone, S.E.; Di Vito, C.; Riccitelli, E.; Abdel Hadi, L.; Bornati, A.; de Rezende, G.;
Giussani, P.; Tringali, C.; et al. Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness
qualities of glioblastoma stem cells. Glia 2014, 62, 1968–1981. [CrossRef] [PubMed]
124. Kawamura, Y.; Takouda, J.; Yoshimoto, K.; Nakashima, K. New aspects of glioblastoma multiforme revealed
by similarities between neural and glioblastoma stem cells. Cell Biol. Toxicol. 2018, 34, 425–440. [CrossRef]
[PubMed]
125. Kimura, A.; Ohmori, T.; Ohkawa, R.; Madoiwa, S.; Mimuro, J.; Murakami, T.; Kobayashi, E.; Hoshino, Y.;
Yatomi, Y.; Sakata, Y. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural
stem cells toward a site of spinal cord injury. Stem Cells 2007, 25, 115–124. [CrossRef] [PubMed]
126. Seidel, S.; Garvalov, B.K.; Wirta, V.; von Stechow, L.; Schänzer, A.; Meletis, K.; Wolter, M.; Sommerlad, D.;
Henze, A.-T.; Nistér, M.; et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible
factor 2α. Brain 2010, 133, 983–995. [CrossRef] [PubMed]
127. Bleau, A.M.; Hambardzumyan, D.; Ozawa, T.; Fomchenko, E.I.; Huse, J.T.; Brennan, C.W.; Holland, E.C.
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor
stem-like cells. Cell Stem Cell 2009, 4, 226–235. [CrossRef]
128. Quezada, C.; Peigñan, L.; Segura, R.; Riquelme, F.; Melo, R.; Rojas, Z.D.; Ayach, F.; San Martín, R.; Cárcamo, J.G.
Study of resistance to chemotherapy mediated by ABC transporters in biopsies of glioblastoma multiforme.
Rev. Med. Chil. 2011, 139, 415–424. [CrossRef]
129. Begicevic, R.-R.; Falasca, M. ABC Transporters in cancer stem cells: Beyond chemoresistance. Int. J. Mol. Sci.
2017, 18, 2362. [CrossRef]
130. Dréan, A.; Rosenberg, S.; Lejeune, F.-X.; Goli, L.; Nadaradjane, A.A.; Guehennec, J.; Schmitt, C.; Verreault, M.;
Bielle, F.; Mokhtari, K.; et al. ATP binding cassette (ABC) transporters: Expression and clinical value in
glioblastoma. J. Neurooncol. 2018, 138, 479–486. [CrossRef]
131. Riboni, L. Cross-talk between tumor stem cells and tumor cells: A glioblastoma strategy to promote
malignancy. Stem Cell Investig. 2018, 5. [CrossRef]
132. Wthamang, X.; Prager, B.C.; Wu, Q.; Kim, L.J.Y.; Gimple, R.C.; Shi, Y.; Yang, K.; Morton, A.R.; Zhou, W.;
Zhu, Z.; et al. Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes
malignant progression. Cell Stem Cell 2018, 22, 514–528.
133. Bougnaud, S.; Golebiewska, A.; Oudin, A.; Keunen, O.; Harter, P.N.; Mäder, L.; Azuaje, F.; Fritah, S.; Stieber, D.;
Kaoma, T.; et al. Molecular crosstalk between tumour and brain parenchyma instructs histopathological
features in glioblastoma. Oncotarget 2016, 7, 31955–31971. [CrossRef]
134. Codrici, E.; Enciu, A.M.; Popescu, I.D.; Mihat, S.; Tanase, C. Glioma stem cells and their microenvironments:
Providers of challenging therapeutic targets. Stem Cells Int. 2016, 2016, 5728438. [CrossRef] [PubMed]
135. Ho, I.A.W.; Shim, W.S.N. Contribution of the microenvironmental niche to glioblastoma heterogeneity.
BioMed Res. Int. 2017, 9634172. [CrossRef] [PubMed]
136. Roos, A.; Ding, Z.; Loftus, J.C.; Tran, N.L. Molecular and microenvironmental determinants of glioma
stem-like cell survival and invasion. Front. Oncol. 2017, 7, 120. [CrossRef] [PubMed]
Cells 2020, 9, 337 28 of 37
137. Hambardzumyan, D.; Gutmann, D.H.; Kettenmann, H. The role of microglia and macrophages in glioma
maintenance and progression. Nat. Neurosci. 2016, 19, 20–27. [CrossRef] [PubMed]
138. Arcuri, C.; Fioretti, B.; Bianchi, R.; Mecca, C.; Tubaro, C.; Beccari, T.; Franciolini, F.; Giambanco, I.; Donato, R.
Microglia-glioma cross-talk: A two way approach to new strategies against glioma. Front. Biosci. 2017, 22,
268–309. [CrossRef]
139. Dello Russo, C.; Lisi, L.; Tentori, L.; Navarra, P.; Graziani, G.; Combs, C.K. Exploiting microglial functions for
the treatment of glioblastoma. Curr. Cancer Drug Targets 2017, 17, 267–281. [CrossRef]
140. Glass, R.; Synowitz, M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol.
2014, 128, 347–362. [CrossRef]
141. Roesch, S.; Rapp, C.; Dettling, S.; Herold-Mende, C. When immune cells turn bad-tumor-associated
microglia/macrophages in glioma. Int. J. Mol. Sci. 2018, 19, 436. [CrossRef]
142. Maceyka, M.; Spiegel, S. Sphingolipid metabolites in inflammatory disease. Nature 2014, 510, 58–67.
[CrossRef]
143. Aoki, M.; Aoki, H.; Ramanathan, R.; Hait, N.C.; Takabe, K. sphingosine-1-phosphate signaling in immune
cells and inflammation: Roles and therapeutic potential. Mediat. Inflamm. 2016, 2016, 8606878. [CrossRef]
144. Di Vito, C.; Abdel Hadi, L.; Navone, S.E.; Marfia, G.; Campanella, R.; Mancuso, M.E.; Riboni, L. Platelet-derived
sphingosine-1-phosphate and inflammation: From basic mechanisms to clinical implications. Platelets 2016,
27, 393–401. [CrossRef] [PubMed]
145. Kitatani, K.; Iwabuchi, K.; Snider, A.; Riboni, L. Sphingolipids in inflammation: From bench to bedside.
Mediat. Inflamm. 2016, 7602526. [CrossRef] [PubMed]
146. Gualtierotti, R.; Guarnaccia, L.; Beretta, M.; Navone, S.E.; Campanella, R.; Riboni, L.; Rampini, P.; Marfia, G.
Modulation of neuroinflammation in the central nervous system: Role of chemokines and sphingolipids.
Adv. Ther. 2017, 34, 396–420. [CrossRef]
147. Hammad, S.M.; Crellin, H.G.; Wu, B.X.; Melton, J.; Anelli, V.; Obeid, L.M. Dual and distinct roles for
sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in raw
macrophages. Prostaglandins Other Lipid Mediat. 2008, 85, 107–114. [CrossRef]
148. Nayak, D.; Huo, Y.; Kwang, W.X.; Pushparaj, P.N.; Kumar, S.D.; Ling, E.A.; Dheen, S.T. Sphingosine kinase 1
regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia. Neuroscience
2010, 166, 132–144. [CrossRef]
149. Marfia, G.; Navone, S.E.; Abdel Hadi, L.; Paroni, M.; Berno, V.; Beretta, M.; Gualtierotti, R.; Ingegnoli, F.;
Levi, V.; Miozzo, M.; et al. The adipose mesenchymal stem cell secretome inhibits inflammatory responses of
microglia: Evidence for an involvement of sphingosine-1-phosphate signalling. Stem Cells Dev. 2016, 25,
1095–1107. [CrossRef]
150. Gibson, C.J.; Hossain, M.M.; Richardson, J.R.; Aleksunes, L.M. Inflammatory regulation of ATP binding
cassette efflux transporter expression and function in microglia. J. Pharm. Exp. Ther. 2012, 343, 650–660.
[CrossRef]
151. Cole, S.P.C. Multidrug resistance protein 1 (MRP1, ABCC1), a “multitasking” ATP-binding cassette (ABC)
transporter. J. Biol. Chem. 2014, 289, 30880–30888. [CrossRef]
152. Matias, D.; Balça-Silva, J.; da Graça, G.C.; Wanjiru, C.M.; Macharia, L.W.; Nascimento, C.P.; Roque, N.R.;
Coelho-Aguiar, J.M.; Pereira, C.M.; Dos Santos, M.F.; et al. Microglia/astrocytes-glioblastoma crosstalk:
Crucial molecular mechanisms and microenvironmental factors. Front. Cell. Neurosci. 2018, 12, 235.
[CrossRef]
153. Zhong, L.; Jiang, X.; Zhu, Z.; Qin, H.; Dinkins, M.B.; Kong, J.N.; Leanhart, S.; Wang, R.; Elsherbini, A.;
Bieberich, E.; et al. Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to
amyloid-beta peptide. Glia 2019, 67, 498–511. [CrossRef] [PubMed]
154. Pilorget, A.; Demeule, M.; Barakat, S.; Marvaldi, J.; Luis, J.; Beliveau, R. Modulation of P-glycoprotein
function by sphingosine kinase-1 in brain endothelial cells. J. Neurochem. 2007, 100, 1203–1210. [CrossRef]
155. Hisano, Y.; Kobayashi, N.; Yamaguchi, A.; Nishi, T. Mouse SPNS2 functions as a spingosine-1-phosphate
transporter in vascular endothelial cells. PLoS ONE 2012, 7, e38941. [CrossRef]
156. Anelli, V.; Bassi, R.; Tettamanti, G.; Viani, P.; Riboni, L. Extracellular release of newly synthesized
sphingosine-1-phosphate by cerebellar granule cells and astrocytes. J. Neurochem. 2005, 92, 1204–1215.
[CrossRef] [PubMed]
Cells 2020, 9, 337 29 of 37
157. Kajimoto, T.; Okada, Y.; Yu, H.; Goparaju, S.K.; Jahangeer, S.; Nakamura, S.-I. Involvement of
sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Mol. Cell. Biol. 2007, 27,
3429–3440. [CrossRef] [PubMed]
158. Brown, P.D.; Jensen, A.W.; Felten, S.J.; Ballman, K.V.; Schaefer, P.L.; Jaeckle, K.A.; Cerhan, J.H.; Buckner, J.C.
Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.
J. Clin. Oncol. 2006, 24, 5427–5433. [CrossRef] [PubMed]
159. Buckingham, S.C.; Campbell, S.L.; Haas, B.R.; Montana, V.; Robel, S.; Ogunrinu, T.; Sontheimer, H. Glutamate
release by primary brain tumors induces epileptic activity. Nat. Med. 2011, 17, 1269–1274. [CrossRef]
160. Strong, A.D.; Indart, M.C.; Hill, N.R.; Daniels, R.L. GL261 glioma tumor cells respond to ATP with an
intracellular calcium rise and glutamate release. Mol. Cell. Biochem. 2018, 446, 53–62. [CrossRef]
161. Marcus, H.J.; Carpenter, K.L.; Price, S.J.; Hutchinson, P.J. In vivo assessment of high-grade glioma biochemistry
using microdialysis: A study of energy-related molecules, growth factors and cytokines. J. Neurooncol. 2010,
97, 11–23. [CrossRef]
162. Haley, E.-M.; Kim, Y. The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma
stem cells and in their in vitro culture. Cancer Lett. 2014, 346, 1–5. [CrossRef]
163. Fessler, E.; Borovski, T.; Medema, J.P. Endothelial cells induce cancer stem cell features in differentiated
glioblastoma cells via bFGF. Mol. Cancer. 2015, 14, 157. [CrossRef]
164. Okamoto, S.; Nitta, M.; Maruyama, T.; Sawada, T.; Komori, T.; Okada, Y.; Muragaki, Y. Bevacizumab changes
vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas.
Brain Tumor Pathol. 2016, 33, 129–136. [CrossRef]
165. Sato, K.; Malchinkhuu, E.; Horiuchi, Y.; Mogi, C.; Tomura, H.; Tosaka, M.; Yoshimoto, Y.; Kuwabara, A.;
Okajima, F. Critical role of ABCA1 transporter in sphingosine 1-phosphate release from astrocytes. J. Neurochem.
2007, 103, 2610–2619. [CrossRef] [PubMed]
166. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
167. Nørøxe, D.S.; Poulsen, H.S.; Lassen, U. Hallmarks of glioblastoma: A systematic review. ESMO Open 2016.
[CrossRef]
168. Mendelson, K.; Evans, T.; Hla, T. Sphingosine 1-phosphate signalling. Development 2014. [CrossRef] [PubMed]
169. Patmanathan, S.N.; Wang, W.; Yap, L.F.; Herr, D.R.; Paterson, I.C. Mechanisms of sphingosine 1-phosphate
receptor signalling in cancer. Cell Signal 2017, 34, 66–75. [CrossRef]
170. Blaho, V.A.; Hla, T. Regulation of mammalian physiology, development, and disease by the sphingosine
1-phosphate and lysophosphatidic acid receptors. Chem. Rev. 2011, 111, 6299–6320. [CrossRef]
171. Yoshida, Y.; Nakada, M.; Sugimoto, N.; Harada, T.; Hayashi, Y.; Kita, D.; Uchiyama, N.; Hayashi, Y.; Yachie, A.;
Takuwa, Y.; et al. Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates
with patient survival. Int. J. Cancer. 2010, 126, 2341–2352. [CrossRef]
172. Marfe, G.; Mirone, G.; Shukla, A.; Di Stefano, C. Sphingosine kinases signalling in carcinogenesis. Mini Rev.
Med. Chem. 2015, 15, 300–314. [CrossRef]
173. El-Shewy, H.M.; Johnson, K.R.; Lee, M.H.; Jaffa, A.A.; Obeid, L.M.; Luttrell, L.M. Insulin-like growth factors
mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate
receptors. J. Biol. Chem. 2006, 281, 31399–313407. [CrossRef] [PubMed]
174. Lebman, D.A.; Spiegel, S. Cross-talk at the crossroads of sphingosine-1-phosphate, growth factors, and
cytokine signaling. J. Lipid Res. 2008, 49, 1388–1394. [CrossRef] [PubMed]
175. El Buri, A.; Adams, D.R.; Smith, D.; Tate, R.J.; Mullin, M.; Pyne, S.; Pyne, N.J. The sphingosine 1-phosphate
receptor 2 is shed in exosomes from breast cancer cells and is N-terminally processed to a short constitutively
active form that promotes extracellular signal regulated kinase activation and DNA synthesis in fibroblasts.
Oncotarget 2018, 9, 29453–29467. [PubMed]
176. Radeff-Huang, J.; Seasholtz, T.M.; Chang, J.W.; Smith, J.M.; Walsh, C.T.; Brown, J.H. Tumor necrosis
factor-α-stimulated cell proliferation is mediated through sphingosine kinase-dependent Akt activation and
cyclin D expression. J. Biol. Chem. 2007, 282, 863–870. [CrossRef]
177. Kapitonov, D.; Allegood, J.C.; Mitchell, C.; Hait, N.C.; Almenara, J.A.; Adams, J.K.; Zipkin, R.E.; Dent, P.;
Kordula, T.; Milstien, S.; et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and
suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 2009, 69, 6915–6923. [CrossRef]
Cells 2020, 9, 337 30 of 37
178. Yu, O.M.; Miyamoto, S.; Brown, J.H. Myocardin-related transcription factor A and Yes-associated protein
exert dual control in G protein-coupled receptor- and RhoA-mediated transcriptional regulation and cell
proliferation. Mol. Cell. Biol. 2016, 36, 39–49.
179. Santosh, V.; Arivazhagan, A.; Sreekanthreddy, P.; Srinivasan, H.; Thota, B.; Srividya, M.R.; Vrinda, M.;
Sridevi, S.; Shailaja, B.C.; Samuel, C.; et al. Grade-specific expression of insulin-like growth factor-binding
proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with
newly diagnosed glioblastoma. Cancer Epidemiol Biomark. Prev. 2010, 19, 1399–1408. [CrossRef]
180. Martin, J.L.; Lin, M.Z.; McGowan, E.M.; Baxter, R.C. Potentiation of growth factor signaling by insulin-like
growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity. J. Biol Chem.
2009, 284, 25542–25552. [CrossRef]
181. Usui, S.; Sugimoto, N.; Takuwa, N.; Sakagami, S.; Takata, S.; Kaneko, S.; Takuwa, Y. Blood lipid mediator
sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression
through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor. J. Biol. Chem. 2004, 279, 12300–12311.
[CrossRef]
182. Van Brocklyn, J.R.; Letterle, C.A.; Snyder, P.J.; Prior, T.W. Sphingosine-1-phosphate stimulates human glioma
cell proliferation through Gi-coupled receptors: Role of ERK MAP kinase and phosphatidylinositol 3-kinase
β. Cancer Lett. 2002, 181, 195–204. [CrossRef]
183. Van Brocklyn, J.R.; Young, N.; Roof, R. Sphingosine-1-phosphate stimulates motility and invasiveness of
human glioblastoma multiforme cells. Cancer Lett. 2003, 199, 53–60. [CrossRef]
184. Sato, K.; Ui, M.; Okajima, F. Differential roles of Edg-1 and Edg-5, sphingosine 1-phosphate receptors, in the
signaling pathways in C6 glioma cells. Mol. Brain Res. 2000, 85, 151–160. [CrossRef]
185. Young, N.; Van Brocklyn, J.R. Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of
glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp. Cell. Res. 2007, 313,
1615–1627. [CrossRef] [PubMed]
186. Estrada-Bernal, A.; Lawler, S.E.; Nowicki, M.O.; Chaudhury, A.R.; Van Brocklyn, J.R. The role of sphingosine
kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J. Neurooncol. 2011, 102, 353–366.
[CrossRef] [PubMed]
187. Oliver, T.G.; Wechsler-Reya, R.J. Getting at the root and stem of brain tumours. Neuron 2004, 42, 885–888.
[CrossRef]
188. Ganguly, D.; Fan, M.; Yang, C.H.; Zbytek, B.; Finkelstein, D.; Roussel, M.F.; Pfeffer, L.M. The critical role
that STAT3 plays in glioma-initiating cells: STAT3 addiction in glioma. Oncotarget 2018, 9, 22095–22112.
[CrossRef] [PubMed]
189. Lee, H.; Deng, J.; Kujawski, M.; Yang, C.; Liu, Y.; Herrmann, A.; Kortylewski, M.; Horne, D.; Somlo, G.;
Forman, S.; et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.
Nat. Med. 2010, 16, 1421–1428. [CrossRef] [PubMed]
190. Hirata, N.; Yamada, S.; Shoda, T.; Kurihara, M.; Sekino, Y.; Kanda, Y. Sphingosine-1-phosphate promotes
expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation. Nat. Commun. 2014, 5,
4806. [CrossRef]
191. Yu, O.M.; Benitez, J.A.; Plouffe, S.W.; Ryback, D.; Klein, A.; Smith, J.; Greenbaum, J.; Delatte, B.; Rao, A.;
Guan, K.L.; et al. YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are
critical for glioblastoma tumorigenicity. Oncogene 2018, 37, 5492–5507. [CrossRef]
192. Hatoum, A.; Mohammed, R.; Zakieh, O. The unique invasiveness of glioblastoma and possible drug targets
on extracellular matrix. Cancer Manag. Res. 2019, 11, 1843–1855. [CrossRef]
193. Kalokhe, G.; Grimm, S.A.; Chandler, J.P.; Helenowski, I.; Rademaker, A.; Raizer, J.J. Metastatic glioblastoma:
Case presentations and a review of the literature. J. Neurooncol. 2012, 107, 21–27. [CrossRef] [PubMed]
194. Lun, M.; Lok, E.; Gautam, S.; Wu, E.; Wong, E.T. The natural history of extracranial metastasis from
glioblastoma multiforme. J. Neurooncol. 2011, 105, 261–273. [CrossRef] [PubMed]
195. Hoelzinger, D.B.; Demuth, T.; Berens, M.E. Autocrine factors that sustain glioma invasion and paracrine
biology in the brain microenvironment. J. Natl. Cancer Inst. 2007, 99, 1583–1593. [CrossRef] [PubMed]
196. Van Brocklyn, J.R. Regulation of cancer cell migration and invasion by sphingosine-1-phosphate. World J.
Biol. Chem. 2010, 1, 307–312. [CrossRef] [PubMed]
197. Lepley, D.; Paik, J.H.; Hla, T.; Ferrer, F. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase
pathway to inhibit tumor cell migration. Cancer Res. 2005, 65, 3788–3795. [CrossRef] [PubMed]
Cells 2020, 9, 337 31 of 37
198. Malchinkhuu, E.; Sato, K.; Maehama, T.; Mogi, C.; Tomura, H.; Ishiuchi, S.; Saito, N.; Kurose, H.; Tomura, H.;
Okajima, F. S1P2 receptors mediate inhibition of glioma cell migration through Rho signaling pathways
independent of PTEN. Biochem. Biophys. Res. Commun. 2008, 366, 963–968. [CrossRef]
199. Sugimoto, N.; Takuwa, N.; Okamoto, H.; Sakurada, S.; Takuwa, Y. Inhibitory and stimulatory regulation of
Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled
sphingosine-1-phosphate receptor isoform. Mol. Cell. Biol. 2003, 23, 1534–1545. [CrossRef]
200. Young, N.; Pearl, D.K.; Van Brocklyn, J.R. Sphingosine-1-phosphate regulates glioblastoma cell invasiveness
through the urokinase plasminogen activator system and CCN1/Cyr61. Mol. Cancer Res. 2009, 7, 23–32.
[CrossRef]
201. Bryan, L.; Paugh, B.S.; Kapitonov, D.; Wilczynska, K.M.; Alvarez, S.M.; Singh, S.K.; Milstien, S.; Spiegel, S.;
Kordula, T. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator
inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: Implications
for invasiveness. Mol. Cancer Res. 2008, 6, 1469–1477. [CrossRef]
202. Zhang, L.; Wang, H.; Ding, K.; Xu, J. FTY720 reduces migration and invasion of human glioblastoma cell
lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. Tumour Biol. 2014, 35, 10707–10714.
[CrossRef]
203. Natarajan, J.; Berrar, D.; Dubitzky, W.; Hack, C.; Zhang, Y.; DeSesa, C.; Van Brocklyn, J.R.; Bremer, E.G. Text
mining of full-text journal articles combined with gene expression analysis reveals a relationship between
sphingosine-1-phosphate and invasiveness of a glioblastoma cell line. BMC Bioinform. 2006, 7. [CrossRef]
[PubMed]
204. Fortier, S.; Labelle, D.; Sina, A.; Moreau, R.; Annabi, B. Silencing of the MT1-MMP/G6PT axis suppresses
calcium mobilization by sphingosine-1-phosphate in glioblastoma cells. FEBS Lett. 2008, 582, 799–804.
[CrossRef] [PubMed]
205. Leclerc, C.; Haeich, J.; Aulestia, F.J.; Kilhoffer, M.C.; Miller, A.L.; Néant, I.; Webb, S.E.; Schaeffer, E.; Junier, M.P.;
Chneiweiss, H.; et al. Calcium signaling orchestrates glioblastoma development: Facts and conjunctures.
Biochim. Biophys. Acta 2016, 1863, 1447–1459. [CrossRef] [PubMed]
206. Toman, R.E.; Spiegel, S. Lysophospholipid receptors in the nervous system. Neurochem. Res. 2002, 27,
619–627. [CrossRef] [PubMed]
207. Pulli, I.; Asghar, M.Y.; Kemppainen, K.; Törnquist, K. Sphingolipid-mediated calcium signaling and its
pathological effects. Biochim. Biophys. Acta Mol. Cell. Res. 2018, 1865, 1668–1677. [CrossRef]
208. Jang, H.S.; Lal, S.; Greenwood, J.A. Calpain 2 is required for glioblastoma cell invasion: Regulation of matrix
metalloproteinase 2. Neurochem. Res. 2010, 35, 1796–1804. [CrossRef]
209. Chen, P.Y.; Csutora, P.; Veyna-Burke, N.A.; Marchase, R.B. Glucose-6-phosphate and Ca2+ sequestration are
mutually enhanced in microsomes from liver, brain, and heart. Diabetes 1998, 47, 874–881. [CrossRef]
210. Belkaid, A.; Currie, J.C.; Desgagnés, J.; Annabi, B. The chemopreventive properties of chlorogenic acid
reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression.
Cancer Cell Int. 2006, 6, 7. [CrossRef]
211. Lepannetier, S.; Zanou, N.; Yerna, X.; Emeriau, N.; Dufour, I.; Masquelier, J.; Muccioli, G.; Tajeddine, N.;
Gailly, P. Sphingosine-1-phosphate-activated TRPC1 channel controls chemotaxis of glioblastoma cells.
Cell Calcium 2016, 60, 373–383. [CrossRef]
212. Annabi, B.; Lachambre, M.P.; Plouffe, K.; Sartelet, H.; Béliveau, R. Modulation of invasive properties of
CD133+ glioblastoma stem cells: A role for MT1-MMP in bioactive lysophospholipid signaling. Mol. Carcinog.
2009, 48, 910–919. [CrossRef]
213. Giussani, P.; Tringali, C.; Riboni, L.; Viani, P.; Venerando, B. Sphingolipids: Key regulators of apoptosis and
pivotal players in cancer drug resistance. Int. J. Mol. Sci. 2014, 15, 4356–4392. [CrossRef]
214. Giussani, P.; Bassi, R.; Anelli, V.; Brioschi, L.; de Zen, F.; Riccitelli, E.; Caroli, M.; Campanella, R.; Gaini, S.M.;
Viani, P.; et al. Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic
death induced by temozolomide and Paclitaxel. Cancer Investig. 2012, 30, 27–37.
215. Vadas, M.; Xia, P.; McCaughan, G.; Gamble, J. The role of sphingosine kinase 1 in cancer: Oncogene or
non-oncogene addiction? Biochim. Biophys. Acta 2008, 1781, 442–447. [CrossRef] [PubMed]
216. Gault, C.R.; Obeid, L.M. Still benched on its way to the bedside: Sphingosine kinase 1 as an emerging target
in cancer chemotherapy. Crit. Rev. Biochem. Mol. Biol. 2011, 46, 342–351. [CrossRef] [PubMed]
Cells 2020, 9, 337 32 of 37
217. Noack, J.; Choi, J.; Richter, K.; Kopp-Schneider, A.; Régnier-Vigouroux, A. A sphingosine kinase inhibitor
combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine
and dihydroceramide, endoplasmic reticulum stress and autophagy. Cell Death Dis. 2014, 5, e1425. [CrossRef]
[PubMed]
218. Oancea-Castillo, L.R.; Klein, C.; Abdollahi, A.; Weber, K.J.; Régnier-Vigouroux, A.; Dokic, I. Comparative
analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on
glioblastoma cell lines. Cancer Biol. Ther. 2017, 18, 400–406. [CrossRef] [PubMed]
219. Bektas, M.; Johnson, S.P.; Poe, WE.; Bigmar, D.D.; Friedman, H.S. A sphingosine kinase inhibitor induces cell
death in temozolomide resistant glioblastoma cells. Cancer Chemother. Pharm. 2009, 64, 1053–1058. [CrossRef]
220. Doan, N.B.; Alhajala, H.; Al-Gizawiy, M.M.; Mueller, W.M.; Rand, S.D.; Connelly, J.M.; Cochran, E.J.;
Chitambar, C.R.; Clark, P.; Kuo, J.; et al. Acid ceramidase and its inhibitors: A de novo drug target and
a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. Oncotarget 2017, 8,
112662–112674. [CrossRef]
221. Radeff-Huang, J.; Seasholtz, T.M.; Matteo, R.G.; Brown, J.H. G protein mediated signaling pathways in
lysophospholipid induced cell proliferation and survival. J. Cell. Biochem. 2004, 92, 949–966. [CrossRef]
222. Koul, D. PTEN Signaling pathways in glioblastoma. Cancer Biol. Ther. 2008, 7, 1321–1325. [CrossRef]
223. Sami, A.; Karsy, M. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: Novel therapeutic
agents and advances in understanding. Tumour Biol. 2013, 34, 1991–2002. [CrossRef] [PubMed]
224. Mantamadiotis, T. Towards targeting PI3K-dependent regulation of gene expression in brain cancer. Cancers
2017, 9, 60. [CrossRef] [PubMed]
225. Brazil, D.P.; Yang, Z.Z.; Hemmings, B.A. Advances in protein kinase B signalling: AKTion on multiple fronts.
Trends Biochem. Sci. 2001, 26, 657–664. [CrossRef]
226. Guan, H.; Song, L.; Cai, J.; Huang, Y.; Wu, J.; Yuan, J.; Li, J.; Li, M. Sphingosine kinase 1 regulates the
Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells. PLoS ONE 1994, 6, e19946.
[CrossRef]
227. Sonoda, Y.; Yamamoto, D.; Sakurai, S.; Hasegawa, M.; Aizu-Yokota, E.; Momoi, T.; Kasahara, T. FTY720, a
novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem. Biophys. Res. Commun.
2001, 281, 282–288. [CrossRef]
228. Zhang, L.; Wang, H.; Ding, K.; Xu, J. FTY720 induces autophagy-related apoptosis and necroptosis in human
glioblastoma cells. Toxicol. Lett. 2015, 236, 43–59. [CrossRef]
229. Giussani, P.; Brioschi, L.; Bassi, R.; Riboni, L.; Viani, P. Phosphatidylinositol 3-kinase/AKT pathway regulates
the endoplasmic reticulum to Golgi traffic of ceramide in glioma cells: A link between lipid signaling
pathways involved in the control of cell survival. J. Biol. Chem. 2009, 284, 5088–5096. [CrossRef]
230. Imran, M.; Rauf, A.; Abu-Izneid, T.; Nadeem, M.; Shariati, M.A.; Khan, I.A.; Imran, A.; Orhan, I.E.; Rizwan, M.;
Atif, M.; et al. Luteolin, a flavonoid, as an anticancer agent: A review. Biomed. Pharm. 2019, 112, 108612.
[CrossRef]
231. Abdel Hadi, L.; Di Vito, C.; Marfia, G.; Ferraretto, A.; Tringali, C.; Viani, P.; Riboni, L. Sphingosine kinase 2
and ceramide transport as key targets of the natural flavonoid luteolin to induce apoptosis in colon cancer
cells. PLoS ONE 2015, 10, e0143384. [CrossRef]
232. Estrada-Bernal, A.; Palanichamy, K.; Ray Chaudhury, A.; Van Brocklyn, J.R. Induction of brain tumor stem
cell apoptosis by FTY720: A potential therapeutic agent for glioblastoma. Neuro-Oncol. 2012, 14, 405–415.
[CrossRef]
233. Brandenburg, S.; Müller, A.; Turkowski, K.; Radev, Y.T.; Rot, S.; Schmidt, C.; Bungert, A.D.; Acker, G.;
Schorr, A.; Hippe, A.; et al. Resident microglia rather than peripheral macrophages promote vascularization
in brain tumors and are source of alternative pro-angiogenic factors. Acta Neuropathol. 2016, 131, 365–378.
[CrossRef]
234. Watters, J.J.; Schartner, J.M.; Badie, B. Microglia function in brain tumors. J. Neurosci. Res. 2005, 81, 447–455.
[CrossRef] [PubMed]
235. Lisi, L.; Ciotti, G.M.; Braun, D.; Kalinin, S.; Currò, D.; Dello Russo, C.; Coli, A.; Mangiola, A.; Anile, C.;
Feinstein, D.L.; et al. Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial
polarization in human glioblastoma and the surrounding normal parenchyma. Neurosci. Lett. 2017, 645,
106–112. [CrossRef] [PubMed]
Cells 2020, 9, 337 33 of 37
236. Zhai, H.; Heppner, F.L.; Tsirka, S.E. Microglia/macrophages promote glioma progression. Glia 2011, 59,
472–485. [CrossRef]
237. Ye, X.-Z.; Xu, S.-L.; Xin, Y.-H.; Yu, S.-C.; Ping, Y.-F.; Chen, L.; Xiao, H.-L.; Wang, B.; Yi, L.; Wang, Q.-L.;
et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1
signaling pathway. J. Immunol. 2012, 189, 444–453. [CrossRef] [PubMed]
238. Gabrusiewicz, K.; Ellert-Miklaszewska, A.; Lipko, M.; Sielska, M.; Frankowska, M.; Kaminska, B.
Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental
gliomas. PLoS ONE 2011, 6, e23902. [CrossRef] [PubMed]
239. Gabrilovich, D.I.; Ostrand-Rosenberg, S.; Bronte, V. Coordinated regulation of myeloid cells by tumours.
Nat. Rev. Immunol. 2012, 12, 253–268. [CrossRef] [PubMed]
240. Komohara, Y.; Ohnishi, K.; Kuratsu, J.; Takeya, M. Possible involvement of the M2 anti-inflammatory
macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216, 15–24. [CrossRef]
241. Prosniak, M.; Harshyne, L.A.; Andrews, D.W.; Kenyon, L.C.; Bedelbaeva, K.; Apanasovich, T.V.;
Heber-Katz, E.; Curtis, M.T.; Cotzia, P.; Hooper, D.C. Glioma grade is associated with the accumulation and
activity of cells bearing M2 monocyte markers. Clin. Cancer Res. 2013, 19, 3776–3786. [CrossRef]
242. Poon, C.C.; Sarkar, S.; Yong, V.W.; Kelly, J.J.P. Glioblastoma-associated microglia and macrophages: Targets
for therapies to improve prognosis. Brain 2017, 140, 1548–1560. [CrossRef]
243. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3, 23–35. [CrossRef] [PubMed]
244. Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.H.; Porta-Pardo, E.; Gao, G.F.;
Plaisier, C.L.; Eddy, J.A.; et al. Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco,
E.G.; Disis ML, Vincent BG, Shmulevich, I. The immune landscape of cancer. Immunity 2018, 48, 812–830.
[CrossRef] [PubMed]
245. Bryan, A.M.; Del Poeta, M. Sphingosine-1-phosphate receptors and innate immunity. Cell. Microbiol. 2018,
20, e12836. [CrossRef] [PubMed]
246. Tham, C.S.; Lin, F.F.; Rao, T.S.; Yu, N.; Webb, M. Microglial activation state and lysophospholipid acid
receptor expression. Int. J. Dev. Neurosci. 2003, 21, 431–443. [CrossRef] [PubMed]
247. Müller, J.; von Bernstorff, W.; Heidecke, C.D.; Schulze, T. Differential S1P receptor profiles on M1- and
M2-polarized macrophages affect macrophage cytokine production and migration. Biomed. Res. Int. 2017,
2017, 7584621. [CrossRef]
248. Awojoodu, A.O.; Ogle, M.E.; Sefcik, L.S.; Bowers, D.T.; Martin, K.; Brayman, K.L.; Lynch, K.R.; Peirce-Cottler, S.M.;
Botchwey, E. Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to
microvessels during implant arteriogenesis. Proc. Natl. Acad. Sci. USA 2013, 110, 13785–13790. [CrossRef]
249. Weichand, B.; Weis, N.; Weigert, A.; Grossmann, N.; Levkau, B.; Brune, B. Apoptotic cells enhance
sphingosine-1-phosphate receptor 1 dependent macrophage migration. Eur. J. Immunol. 2013, 43, 3306–3313.
[CrossRef]
250. Weichand, B.; Popp, R.; Dziumbla, S.; Mora, J.; Strack, E.; Elwakeel, E.; Frank, A.C.; Scholich, K.; Pierre, S.;
Syed, S.N.; et al. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via
NLRP3/IL-1beta. J. Exp. Med. 2017, 214, 2695–2713. [CrossRef]
251. Marx, S.; Splittstöhser, M.; Kinnen, F.; Moritz, E.; Joseph, C.; Paul, S.; Paland, H.; Seifert, C.; Marx, M.;
Böhm, A.; et al. Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma
multiforme patients. Oncotarget 2018, 9, 25860–25876. [CrossRef]
252. Weigert, A.; Olesch, C.; Brüne, B. Sphingosine-1-phosphate and macrophage biology-how the sphinx tames
the big eater. Front. Immunol. 2019, 10, 1706. [CrossRef]
253. Gaire, B.P.; Lee, C.H.; Sapkota, A.; Lee, S.Y.; Chun, J.; Cho, H.J.; Nam, T.G.; Choi, J.W. Identification of
sphingosine 1-phosphate receptor subtype 1 (S1P1) as a pathogenic factor in transient focal cerebral ischemia.
Mol. Neurobiol. 2018, 55, 2320–2332. [CrossRef] [PubMed]
254. Kim, G.S.; Yang, L.; Zhang, G.; Zhao, H.; Selim, M.; McCullough, L.D.; Kluk, M.J.; Sanchez, T. Critical role of
sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke.
Nat. Commun. 2015, 6, 7893. [CrossRef] [PubMed]
255. Gaire, B.P.; Song, M.R.; Choi, J.W. Sphingosine 1-phosphate receptor subtype 3 (S1P3) contributes to brain
injury after transient focal cerebral ischemia via modulating microglial activation and their M1 polarization.
J. Neuroinflamm. 2018, 15, 284. [CrossRef] [PubMed]
Cells 2020, 9, 337 34 of 37
256. Sapkota, A.; Gaire, B.P.; Kang, M.G.; Choi, J.W. S1P2 contributes to microglial activation and M1 polarization
following cerebral ischemia through ERK1/2 and JNK. Sci. Rep. 2019, 9, 12106. [CrossRef]
257. Gaire, B.P.; Bae, Y.J.; Choi, J.W. S1P1 Regulates M1/M2 polarization toward brain injury after transient focal
cerebral ischemia. Biomol. Ther. (Seoul) 2019, 27, 522–529. [CrossRef]
258. Hughes, J.E.; Srinivasan, S.; Lynch, K.R.; Proia, R.L.; Ferdek, P.; Hedrick, C.C. Sphingosine-1-phosphate
induces an anti-inflammatory phenotype in macrophages. Circ. Res. 2008, 102, 950–958. [CrossRef]
259. Park, S.J.; Lee, K.P.; Kang, S.; Lee, J.; Sato, K.; Chung, H.Y.; Okajima, F.; Im, D.S. Sphingosine 1-phosphate
induced anti-atherogenic and atheroprotective M2 macrophage polarization through IL-4. Cell. Signal. 2014,
26, 2249–2258. [CrossRef]
260. Rodriguez, Y.I.; Campos, L.E.; Castro, M.G.; Aladhami, A.; Oskeritzian, C.A.; Alvarez, S.E. Sphingosine-1
phosphate: A new modulator of immune plasticity in the tumor microenvironment. Front. Oncol. 2016,
6, 218. [CrossRef]
261. Weigert, A.; Tzieply, N.; von Knethen, A.; Johann, A.M.; Schmidt, H.; Geisslinger, G.; Brüne, B. Tumor cell
apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol. Biol. Cell. 2007, 18, 3810–3819.
[CrossRef]
262. Weigert, A.; Schiffmann, S.; Sekar, D.; Ley, S.; Menrad, H.; Werno, C.; Grosch, S.; Geisslinger, G.; Brüne, B.
Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages
towards an anti-inflammatory phenotype. Int. J. Cancer. 2009, 125, 2114–2121. [CrossRef]
263. Weis, N.; Weigert, A.; von Knethen, A.; Brüne, B. Heme oxygenase-1 contributes to an alternative macrophage
activation profile induced by apoptotic cell supernatants. Mol. Biol. Cell. 2009, 20, 1280–1288. [CrossRef]
[PubMed]
264. Mrad, M.; Imbert, C.; Garcia, V.; Rambow, F.; Therville, N.; Carpentier, S.; Ségui, B.; Levade, T.; Azar, R.;
Marine, J.C.; et al. Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting
M1 macrophage response in melanoma. Oncotarget 2016, 7, 71873–71886. [CrossRef]
265. Weigert, A.; von Knethen, A.; Thomas, D.; Faria, I.; Namgaladze, D.; Zezina, E.; Fuhrmann, D.; Petcherski, A.;
Heringdorf, D.M.Z.; Radeke, H.H.; et al. Sphingosine kinase 2 is a negative regulator of inflammatory
macrophage activation. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2019, 1864, 1235–1246. [CrossRef]
[PubMed]
266. Liu, J.; Zhou, Q.; Wu, C.P.; Xu, Y.W.; Liu, W.L.; Zhao, H.F.; Li, W.P. SPHK2 protein expression, Ki-67 index
and infiltration of tumor-associated macrophages (TAMs) in human glioma. Histol. Histopathol. 2018, 33,
987–994. [PubMed]
267. Luo, B.; Gan, W.; Liu, Z.; Shen, Z.; Wang, J.; Shi, R.; Liu, Y.; Liu, Y.; Jiang, M.; Zhang, Z.; et al. Erythropoietin
signaling in macrophages promotes dying cell clearance and immune tolerance. Oncotarget 2015, 6, 2101–2119.
268. Gielen, P.R.; Schulte, B.M.; Kers-Rebel, E.D.; Verrijp, K.; Petersen-Baltussen, H.M.; ter Laan, M.;
Wesseling, P.; Adema, G.J. Increase in both CD14-positive a nd CD15-positive myeloid-derived suppressor
cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived
suppressor cells in glioma tissue. J. Neuropathol. Exp. Neurol. 2015, 74, 390–400. [CrossRef]
269. Gabrusiewicz, K.; Rodriguez, B.; Wei, J.; Hashimoto, Y.; Healy, L.M.; Maiti, S.N.; Thomas, G.; Zhou, S.;
Wang, Q.; Elakkad, A.; et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage
phenotype. JCI Insight 2016, 1, 85841. [CrossRef]
270. Li, Y.; Zhou, T.; Wang, Y.; Ning, C.; Lv, Z.; Han, G.; Morris, J.C.; Taylor, E.N.; Wang, R.; Xiao, H.;
et al. The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC
accumulation. Oncogene 2017, 36, 3760–3771. [CrossRef]
271. Woroniecka, K.I.; Rhodin, K.E.; Chongsathidkiet, P.; Keith, K.A.; Fecci, P.E. T-Cell Dysfunction in glioblastoma:
Applying a new framework. Clin. Cancer Res. 2018, 24, 3792–3802. [CrossRef]
272. Matloubian, M.; Lo, C.G.; Cinamon, G.; Lesneski, M.J.; Xu, Y.; Brinkmann, V.; Allende, M.L.; Proia, R.L.;
Cyster, J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor
1. Nature 2004, 427, 355–360. [CrossRef]
273. Schwab, S.R.; Cyster, J.G. Finding a way out: Lymphocyte egress from lymphoid organs. Nat. Immunol. 2007,
8, 1295–1301. [CrossRef] [PubMed]
274. Chongsathidkiet, P.; Jackson, C.; Koyama, S.; Loebel, F.; Cui, X.; Farber, S.H.; Woroniecka, K.; Elsamadicy, A.A.;
Dechant, C.A.; Kemeny, H.R.; et al. Sequestration of T cells in bone marrow in the setting of glioblastoma
and other intracranial tumors. Nat. Med. 2018, 24, 1459–1468. [CrossRef]
Cells 2020, 9, 337 35 of 37
275. Linkous, A.G.; Yazlovitskaya, E.M. Angiogenesis in glioblastoma multiforme: Navigating the maze.
Anticancer Agents Med. Chem. 2011, 11, 712–718. [CrossRef] [PubMed]
276. Calabrese, C.; Poppleton, H.; Kocak, M.; THogg, L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.;
Finklestein, D.; Allen, M.; et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11, 69–82.
[CrossRef] [PubMed]
277. Gilbertson, R.J.; Rich, J.N. Making a tumour’s bed: Glioblastoma stem cells and the vascular niche. Nat. Rev.
Cancer 2007, 7, 733–736. [CrossRef] [PubMed]
278. Charles, N.; Holland, E.C. The perivascular niche microenvironment in brain tumor progression. Cell Cycle
2010, 9, 3012–3021. [CrossRef]
279. Krock, B.L.; Skuli, N.; Simon, M.C. Hypoxia-induced angiogenesis: Good and evil. Genes Cancer 2011, 2,
1117–1133. [CrossRef]
280. Onishi, M.; Ichikawa, T.; Kurozumi, K.; Date, I. Angiogenesis and invasion in glioma. Brain Tumor Pathol.
2011, 28, 13–24. [CrossRef]
281. Takano, S. Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular
mechanisms of tumor vessel formation. Brain Tumor Pathol. 2012, 29, 73–86. [CrossRef]
282. Jain, R.K.; di Tomaso, E.; Duda, D.G.; Loeffler, J.S.; Sorensen, A.G.; Batchelor, T.T. Angiogenesis in brain
tumours. Nat. Rev. Neurosci. 2007, 8, 610–622. [CrossRef]
283. Chen, W.; He, D.; Li, Z.; Zhang, X.; Pan, D.; Chen, G. Overexpression of vascular endothelial growth factor
indicates poor outcomes of glioma: A systematic review and meta-analysis. Int. J. Clin. Exp. Med. 2015, 8,
8709–8719. [PubMed]
284. Ader, I.; Brizuela, L.; Bouquerel, P.; Malavaud, B.; Cuvillier, O. Sphingosine kinase 1: A new modulator
of hypoxia inducible factor 1α during hypoxia in human cancer cells. Cancer Res. 2008, 68, 8635–8642.
[CrossRef]
285. Bulnes, S.; Bengoetxea, H.; Ortuzar, N.; Argandoña, E.G.; Garcia-Blanco, A.I.; Rico-Barrio, I.; Lafuente, J.V.
Angiogenic signalling pathways altered in gliomas: Selection mechanisms for more aggressive neoplastic
subpopulations with invasive phenotype. J. Signal. Trans. 2012, 2012, 597915. [CrossRef] [PubMed]
286. Limaye, V. The role of sphingosine kinase and sphingosine-1-phosphate in the regulation of endothelial cell
biology. Endothelium 2008, 15, 101–112. [CrossRef]
287. Argraves, K.M.; Wilkerson, B.A.; Argraves, W.S. Sphingosine-1-phosphate signalling in vasculogenesis and
angiogenesis. World J. Biol. Chem. 2010, 1, 291–297. [CrossRef]
288. Lucke, S.; Levkau, B. Endothelial functions of sphingosine-1-phosphate. Cell Physiol. Biochem. 2010, 26, 87–96.
[CrossRef]
289. Sun, H.Y.; Wei, S.P.; Xu, R.C.; Xu, P.X.; Zhang, W.C. Sphingosine-1-phosphate induces human endothelial VEGF
and MMP-2 production via transcription factor ZNF580: Novel insights into angiogenesis. Biochem. Biophys.
Res. Commun. 2010, 395, 361–366. [CrossRef]
290. Liu, Y.; Wada, R.; Yamashita, T.; Mi, Y.; Deng, C.X.; Hobson, J.P.; Rosenfeldt, H.M.; Nava, V.E.; Chae, S.S.;
Lee, M.J.; et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular
maturation. J. Clin. Investig. 2000, 106, 951–961. [CrossRef]
291. Osada, M.; Yatomi, Y.; Ohmori, T.; Ikeda, H.; Ozaki, Y. Enhancement of sphingosine 1-phosphate-induced
migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem. Biophys.
Res. Commun. 2002, 299, 483–487. [CrossRef]
292. Igarashi, J.; Erwin, P.A.; Dantas, A.P.; Chen, H.; Michel, T. VEGF induces S1P1 receptors in endothelial cells:
Implications for cross-talk between sphingolipid and growth factor receptors. Proc. Natl. Acad. Sci. USA
2003, 100, 10664–10669. [CrossRef]
293. Justus, C.R.; Sanderlin, E.J.; Yang, L.V. Molecular connections between cancer cell metabolism and the tumor
microenvironment. Int. J. Mol. Sci. 2015, 16, 11055–11086. [CrossRef] [PubMed]
294. Cloughesy, T.F.; Cavenee, W.K.; Mischel, P.S. Glioblastoma: From molecular pathology to targeted treatment.
Annu. Rev. Pathol. 2014, 9, 1–25. [CrossRef] [PubMed]
295. Kucharzewska, P.; Christianson, H.C.; Belting, M. Global profiling of metabolic adaptation to hypoxic stress
in human glioblastoma cells. PLoS ONE 2015, 10, 10–1371. [CrossRef] [PubMed]
296. Clark, P.M.; Mai, W.X.; Cloughesy, T.F.; Nathanson, D.A. Emerging approaches for targeting metabolic
vulnerabilities in malignant glioma. Curr. Neurol. Neurosci. Rep. 2016, 16. [CrossRef] [PubMed]
Cells 2020, 9, 337 36 of 37
297. Jiang, W.; Finniss, S.; Cazacu, S.; Xiang, C.; Brodie, Z.; Mikkelsen, T.; Poisson, L.; Shackelford, D.B.; Brodie, C.
Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Oncotarget
2016, 7, 56456–56470. [CrossRef] [PubMed]
298. Talasila, K.M.; Rosland, G.V.; Hagland, H.R.; Eskilsson, E.; Flones, I.H.; Fritah, S.; Azuaje, F.; Atai, N.;
Harter, P.N.; Mittelbronn, M.; et al. The angiogenic switch leads to a metabolic shift in human glioblastoma.
Neuro-Oncol. 2017, 19, 383–393. [CrossRef] [PubMed]
299. Lunt, S.Y.; Vander Heiden, M.G. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation.
Annu. Rev. Cell. Dev. Biol. 2011, 27, 441–464. [CrossRef]
300. Lu, J.; Tan, M.; Cai, Q. The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an
anti-metastasis mechanism. Cancer Lett. 2015, 356, 156–164. [CrossRef]
301. Altman, B.J.; Stine, Z.E.; Dang, C.V. From Krebs to clinic: Glutamine metabolism to cancer therapy.
Nat. Rev. Cancer 2016, 16, 619–634. [CrossRef]
302. Libby, C.J.; Tran, A.N.; Scott, S.E.; Griguer, C.; Hjelmeland, A.B. The pro-tumorigenic effects of metabolic
alterations in glioblastoma including brain tumor initiating cells. Biochim. Biophys. Acta Rev. Cancer 2018,
1869, 175–188. [CrossRef]
303. Watson, D.G.; Tonelli, F.; Alossaimi, M.; Williamson, L.; Chan, E.; Gorshkova, I.; Berdyshev, E.; Bittman, R.;
Pyne, N.J.; Pyne, S. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate
cancer cells. Cell Signal 2013, 25, 1011–1017. [CrossRef] [PubMed]
304. Bernacchioni, C.; Ghini, V.; Cencetti, F.; Japtok, L.; Donati, C.; Bruni, P.; Turano, P. NMR metabolomics
highlights sphingosine kinase-1 as a new molecular switch in the orchestration of aberrant metabolic
phenotype in cancer cells. Mol. Oncol. 2017, 11, 517–533. [CrossRef] [PubMed]
305. Shen, Y.; Zhao, S.; Wang, S.; Pan, X.; Zhang, Y.; Xu, J.; Jiang, Y.; Li, H.; Zhang, Q.; Gao, J.; et al. S1P/S1PR3 axis
promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. EBioMedicine 2019, 40, 210–223.
[CrossRef] [PubMed]
306. Wang, G.; Wang, J.J.; Fu, X.L.; Guang, R.; To, S.T. Advances in the targeting of HIF-1α and future therapeutic
strategies for glioblastoma multiforme. Oncol. Rep. 2017, 37, 657–670. [CrossRef] [PubMed]
307. Quinones, A.; Le, A. The multifaceted metabolism of glioblastoma. Adv. Exp. Med. Biol. 2018, 1063, 59–72.
[PubMed]
308. Garnier, D.; Renoult, O.; Alves-Guerra, M.C.; Paris, F.; Pecqueur, C. Glioblastoma stem-like cells, metabolic
strategy to kill a challenging target. Front. Oncol. 2019, 9. [CrossRef] [PubMed]
309. Ng, W.; Pébay, A.; Drummond, K.; Burgess, A.; Kaye, A.H.; Morokoff, A. Complexities of lysophospholipid
signalling in glioblastoma. J. Clin. Neurosci. 2014, 21, 893–898. [CrossRef]
310. Tabuchi, S. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: Proposal of a novel
potential therapeutic target for treating glioblastoma multiforme. Lipids Health Dis. 2015, 14, 56. [CrossRef]
311. Clair, T.; Aoki, J.; Koh, E.; Bandle, R.W.; Nam, S.W.; Ptaszynska, M.M.; Mills, G.B.; Schiffmann, E.; Liotta, L.A.;
Stracke, M.L. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration,
sphingosine-1-phosphate. Cancer Res. 2003, 63, 5446–5453.
312. van Meeteren, L.A.; Ruurs, P.; Christodoulou, E.; Goding, J.W.; Takakusa, H.; Kikuchi, K.; Perrakis, A.;
Nagano, T.; Moolenaar, W.H. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
J. Biol. Chem. 2005, 280, 21155–21161. [CrossRef]
313. Benesch, M.G.; Zhao, Y.Y.; Curtis, J.M.; McMullen, T.P.; Brindley, D.N. Regulation of autotaxin expression and
secretion by lysophosphatidate and sphingosine 1-phosphate. J. Lipid Res. 2015, 56, 1134–1144. [CrossRef]
314. Shida, D.; Fang, X.; Kordula, T.; Takabe, K.; Lepine, S.; Alvarez, S.E.; Milstien, S.; Spiegel, S. Cross-talk
between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to
promote gastric cancer cell motility and invasion. Canc. Res. 2008, 68, 6569–6577. [CrossRef] [PubMed]
315. Kunkel, G.T.; Maceyka, M.; Milstien, S.; Spiegel, S. Targeting the sphingosine-1-phosphate axis in cancer,
inflammation and beyond. Nat. Rev. Drug Discov. 2013, 12, 688–702. [CrossRef] [PubMed]
316. Lewis, C.S.; Voelkel-Johnson, C.; Smith, C.D. Targeting sphingosine kinases for the treatment of cancer.
Adv. Cancer Res. 2018, 140, 295–325.
317. Zheng, X.; Li, W.; Ren, L.; Liu, J.; Pang, X.; Chen, X.; Kang, D.; Wang, J.; Du, G. The sphingosine
kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy. Pharmacol. Ther.
2019, 195, 85–99. [CrossRef] [PubMed]
Cells 2020, 9, 337 37 of 37
318. Nguyen, H.S.; Awad, A.J.; Shabani, S.; Doan, N. Molecular targeting of acid ceramidase in glioblastoma: A
review of its role, potential treatment, and challenges. Pharmaceutics 2018, 10, 45. [CrossRef] [PubMed]
319. Nagahashi, M.; Takabe, K.; Terracina, K.P.; Soma, D.; Hirose, Y.; Kobayashi, T.; Matsuda, Y.; Wakai, T.
Sphingosine-1-phosphate transporters as targets for cancer therapy. Biomed. Res. Int. 2014, 2014, 651727.
[CrossRef]
320. O’Sullivan, S.; Dev, K.K. Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for
CNS-related diseases. Neuropharmacology 2017, 113, 597–607. [CrossRef]
321. Xie, Z.; Liu, H.; Geng, M. Targeting sphingosine-1-phosphate signaling for cancer therapy. Sci. China Life Sci.
2017, 60, 585–600. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
